Iron deficiency anaemia: Managing symptoms and supporting self-care

A handbook for pharmacists

2024
Colophon

Copyright 2024 International Pharmaceutical Federation (FIP)

International Pharmaceutical Federation (FIP)
Andries Bickerweg 5
2517 JP The Hague
The Netherlands
www.fip.org

All rights reserved. No part of this publication may be stored in any retrieval system or transcribed by any form or means — electronic, mechanical, recording, or otherwise — without citation of the source. FIP shall not be held liable for any damages incurred resulting from the use of any data or information from this report. All measures have been taken to ensure accuracy of the data and information presented in this report.

Authors and editors:
Professor Ian Bates (FIP Global Pharmaceutical Observatory Director)
Dr Sherly Meilianti (FIP Data and Intelligence Specialist)
Ms Nisa Masyitah (FIP Project and Data Support Coordinator)
Ms Farah Aqqad (FIP Data Integration Specialist)
Ms Grace Adebayo (FIP Global Pharmaceutical Observatory Intern)

Recommended citation:
ISBN: 9789083092898

Cover image:
© Shidlovski | Istockphoto.com &
© Chernetskaya | Dreamstime.com
Contents

Executive summary ................................................................................................................................................ 5
Acknowledgements ............................................................................................................................................... 6
1 Introduction ..................................................................................................................................................... 7
  1.1 Background ........................................................................................................................................................ 7
  1.2 Global policies and interventions on anaemia .................................................................................................. 7
  1.3 Iron deficiency anaemia .................................................................................................................................... 8
  1.4 FIP contribution to support pharmacists’ roles in managing anaemia .............................................................. 8
  1.5 Handbook development to support pharmacists’ roles in IDA ......................................................................... 9
2 Role of pharmacists in IDA .............................................................................................................................. 11
  2.1 Pharmacists’ roles in supporting self-care with regard to IDA ........................................................................ 11
  2.2 Pharmacists’ roles in managing IDA across practice sectors ........................................................................... 12
  2.3 Educational needs to support pharmacists’ role in IDA .................................................................................. 13
3 IDA management in adults ............................................................................................................................. 15
  3.1 Identification and investigation of IDA ............................................................................................................ 15
    3.1.1 Signs and symptoms .................................................................................................................................. 15
    3.1.2 Medical and medication histories ............................................................................................................ 15
    3.1.3 Examination and investigation ............................................................................................................... 15
    3.1.4 Referrals .................................................................................................................................................. 17
  3.2 Pharmacological treatments ........................................................................................................................... 19
    3.2.1 Iron repletion therapy ............................................................................................................................ 19
    3.2.2 Blood transfusion for severe IDA ............................................................................................................ 24
  3.3 Non-pharmacological interventions ................................................................................................................ 25
    3.3.1 Dietary modification .................................................................................................................................. 25
    3.3.2 Lifestyle modification ............................................................................................................................. 27
  3.4 Supporting pharmacists’ roles in IDA treatment and management .................................................................... 27
    3.4.1 Patient counselling guide steps ............................................................................................................... 27
    3.4.2 Flowchart of IDA treatment and management in primary and secondary care settings ........................ 29
4 IDA management in special populations ......................................................................................................... 31
  4.1 Paediatrics ....................................................................................................................................................... 31
  4.2 Non-pregnant women of reproductive age ..................................................................................................... 32
    4.2.1 Heavy menstrual bleeding ....................................................................................................................... 32
    4.2.2 Women with birth control ....................................................................................................................... 34
  4.3 Pregnant women and breastfeeding mothers ................................................................................................. 34
    4.3.1 Oral iron supplements ............................................................................................................................ 34
    4.3.2 Parenteral iron therapy .......................................................................................................................... 35
  4.4 The elderly and patients with chronic diseases ............................................................................................... 37
    4.4.1 Elderly patients ....................................................................................................................................... 37
    4.4.2 Patients with chronic diseases ............................................................................................................... 37
  4.5 Patients with chronic blood loss ..................................................................................................................... 39
    4.5.1 Gastrointestinal bleeding ....................................................................................................................... 39
    4.5.2 Bleeding disorders .................................................................................................................................. 39
  4.6 Individuals on strict diets .................................................................................................................................. 40
5 IDA prevention ............................................................................................................................................... 41
  5.1 Increasing awareness and public education .................................................................................................... 41
  5.2 Identification and screening of high-risk individuals in the population ......................................................... 41
  5.3 Increasing iron intakes ..................................................................................................................................... 42
    5.3.1 Iron supplements ....................................................................................................................................... 42
    5.3.2 Dietary modification .................................................................................................................................. 43
    5.3.3 Iron fortification ....................................................................................................................................... 43
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.3.4 Biofortification</td>
<td>43</td>
</tr>
<tr>
<td>5.4 Monitoring and evaluation</td>
<td>44</td>
</tr>
<tr>
<td>6 Summary and conclusions</td>
<td>45</td>
</tr>
<tr>
<td>7 References</td>
<td>46</td>
</tr>
</tbody>
</table>
Executive summary

Anaemia is a global public health concern, affecting individuals of all ages and demographic groups, with implications for health, morbidity and mortality. It stems from many factors, including diet, chronic illnesses, infections, hereditary blood disorders and other conditions related to blood loss and reduced haemoglobin levels. While anaemia manifests as decreased haemoglobin or haematocrit levels, iron deficiency anaemia is the most prevalent type, and iron is a crucial element for growth and development and a component of haemoglobin.

In 2022, the International Pharmaceutical Federation (FIP) explored the role of pharmacists in anaemia management, emphasising the need for an educational guide to support pharmacists, particularly in addressing iron deficiency anaemia (IDA). IDA, which affects 1.2 billion individuals worldwide, is preventable and treatable, highlighting the importance of early detection. Pharmacists, as accessible healthcare providers, bear a critical responsibility to educate patients, tailored to factors like age, sex, underlying conditions and the causes of IDA, encompassing self-care interventions and various management approaches. Pharmacists can promote a holistic approach to self-care and can support mitigation of the impact of this condition on overall health and well-being.

This handbook aims to provide a comprehensive guide for pharmacists to manage iron deficiency anaemia effectively, including for more vulnerable populations. It equips pharmacists with information on treatment options, managing special populations, screening and preventive measures for IDA. Nutrition, emphasising iron-rich diets and physical activity, is also described.

Addressing other types of anaemia is equally important, necessitating the identification and tailored treatment of their underlying causes. This handbook only covers anaemia treatment and management due to iron deficiency; there remains a need to further develop resources and guidelines for the management of other types of anaemia.

Further professional programmes designed to enhance pharmacists’ competence in managing IDA, such as in a format of workshops, self-directed learning opportunities, or continuing professional development courses, are recommended. Collaboration with national professional leadership bodies would facilitate the organisation of workshops, self-directed learning initiatives, and the sharing of best practices.

In conclusion, this handbook serves as an invaluable resource for pharmacists in managing IDA, underpinning the importance of pharmacists’ role in screening, managing, treating, patient education and holistic self-care practices. It is recommended to accompany this handbook with further CPD and resources for other types of anaemia.
Acknowledgements

The development of this report was led by the co-authors, and the content of this report has been produced independently by the authors.

FIP acknowledges the following experts for their support in reviewing the handbook:

Prof. Ally Murji Fatima MD, MPH
Prof. Malcolm G. Munro MD, FACOG, FRCSC
Prof. Hilary O. D. Critchley
The International Federation of Gynecology and Obstetrics Committee

Mdm. Susan Tang Siew Chin
Malaysia Pharmacist Society/Sarawak Pharmaceutical Society
Malaysia

Prof. (Dr) Priscilla How, PharmD, BCPS
Associate professor and principal clinical pharmacist (nephrology), National University Hospital
Department of Pharmacy, Faculty of Science, National University of Singapore
Singapore

Chuang Shen Hui
Principal pharmacist (clinical), Division of Pharmacy, Tan Tock Seng Hospital
Singapore

Rosalynn L. Pangan, RPh, MBA-H
Philippine Pharmacists Association
Philippines

Prof. Linda Tahaineh
Faculty of Pharmacy,
Jordan University of Science and Technology,
Jordan

Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Clinical professor, University of Connecticut School of Pharmacy
United States

Jenae Robertz, PharmD
Clinical pharmacist, Great Lakes Bay Health Centers
United States

Dr Josep M. Guiu-Segura
Director of pharmacy and medicines at Consortium of Health and Social Care of Catalonia
Associate professor, Faculty of Pharmacy and Food Sciences, University of Barcelona
Spain

Mary Ann Kliethermes, BS Pharm, PharmD, FAPhA, FCIOM
Director of medication safety and quality, American Society of Health-System Pharmacists
United States

FIP also thanks the FIP Programme Team members, the FIP Community Pharmacy Section, and the FIP Hospital Pharmacy Section for their support in providing expert review panels to review this handbook.

The handbook was reviewed by FIP chief executive officer Dr Catherine Duggan. This handbook was supported by unrestricted funds from Procter & Gamble Health.
1 Introduction

The sections in this handbook were developed following a structured scoping review process using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guideline. The steps involved can be seen in Figure 1.

1.1 Background

Anaemia is a major global public health concern, closely tied to socioeconomic status and education,\(^1\) and could indicate poor nutrition and health.\(^3\) Anaemia involves a decreased red blood cell count or haemoglobin concentration, which impairs oxygen transport in the body.\(^3\) The World Health Organization (WHO) defines anaemia as haemoglobin levels below 12.0 g/dl in non-pregnant, reproductive-aged women and 13.0 g/dl in males.\(^4\) It is estimated that half of the global burden of anaemia\(^7\) is due to iron deficiency.

Globally, anaemia affects around 40% of children (6–59 months), 37% of pregnant women, and 30% of women (15–49 years).\(^1\) The WHO African and South-East Asian regions are most affected.\(^8\) In 2019, 1.8 billion people (23% of the world) suffered from anaemia,\(^4\) increasing to 1.9 billion in 2021.\(^5\) Males exhibited a lower prevalence than females across all age groups. In 2021, the prevalence for all age groups was 17.5% in males and 31.2% in females.\(^9\) A critical concern is for women of reproductive age, as anaemia contributes to maternal deaths,\(^10\) and affects about two in five pregnant women and one in three non-pregnant women in this group.\(^8\)\(^11\)

The underlying causes of anaemia are multifactorial,\(^12\) including biological, socioeconomic and ecological influences.\(^1\) The causes may vary by population and age; for example, nutritional deficiencies and chronic diseases are the most common causes in children and older adults, respectively.\(^2\) Causes of anaemia can be nutrition-specific (e.g., insufficient intake or poor absorption of micronutrients), non-nutritional specific (e.g., inherited haemoglobinopathies and infectious diseases), or a combination of these; each of these factors may have a social component.\(^8\) Low socioeconomic status and limited education increase risk through poor living conditions, inadequate diets and restricted healthcare access.\(^1\) There were variations in the distribution of anaemia cases based on gender and country, but dietary iron deficiency, haemoglobinopathies and haemolytic anaemias (13.7%) accounted for most cases worldwide.\(^4\) Looking specifically at low and lower-middle income countries, iron deficiency and malaria are the most common causes of anaemia, particularly in rural and poor households with no formal education.\(^1\) Comprehensive approaches are needed to address this multifaceted problem.\(^1\)

1.2 Global policies and interventions on anaemia

As a health concern affecting maternal, infant and child well-being, anaemia recognition and treatment is significant for global policy and intervention agendas. As long ago as 2012, the World Health Assembly (WHA) approved global targets for maternal, infant and young child nutrition, which encompasses the ambitious objective of halving anaemia
prevalence in women aged 15 to 49 by 2025.1, 13 This effort is reinforced by the United Nations 2030 Agenda for Sustainable Development Goals (SDGs), which highlights anaemia in women of the same age group as a key indicator of 2.2.3 of the SDGs.1, 8 This commitment was affirmed at the 2021 Nutrition for Growth Summit, where the WHO pledged to develop an encompassing framework for preventing, diagnosing and managing anaemia through a holistic approach.1 Additionally, an Anaemia Action Alliance was created to align actions in reducing anaemia. 1

Progress in reducing anaemia prevalence has been insufficient. While some progress has been made in combating anaemia, the most substantial declines have been seen among males and adults aged 20–74 years.9 In contrast, young children (under five years) and women of reproductive age have not experienced the same improvement.9 From 2000 to 2019, global estimates of anaemia prevalence slightly decreased from 31% to 30% among non-pregnant women and 41% to 36% among pregnant women. There is a global prevalence of 40% in 2019 for infants and children, exceeding 70% in specific countries. This status quo mandates comprehensive changes on multiple fronts, necessitating the involvement of policymakers, politicians, pharmacists and clinicians to address the complex factors contributing to anaemia.12

1.3 Iron deficiency anaemia

As stated above, it is estimated that half of the global burden of anaemia7 is due to iron deficiency (ID). ID is characterised by a reduction in the body’s total iron content and is a global nutritional concern affecting over two billion people.14, 15 It may or may not progress to iron deficiency anaemia (IDA), a common form of chronic anaemia.15 ID can result from insufficient iron intake or absorption and can also occur due to clinical issues such as chronic gastrointestinal bleeding or iron depletion, like blood donation.16 As ID progresses, it initially mobilises iron from ferritin, primarily stored in the liver. This redirection of iron resources to support red blood cell production occurs at the expense of other essential bodily functions and precedes the onset of anaemia, leading to IDA.16 According to International Classification of Diseases (ICD)-10 and Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT), IDA is categorised as nutritional anaemia (disorder) or nutritional deficiency associated condition (disorder) and it is interpreted as haemoglobin or red blood cell count below reference range.17, 18

Both ID and IDA significantly impact an individual’s well-being.19 ID alone adversely affects quality of life and cognitive function.16 Chronic conditions like chronic kidney disease, heart failure and inflammatory diseases are often associated with ID and contribute to increased mortality risk.20 ID, with or without anaemia, is also a common complication of cancer.20 In mild-to-moderate cases, symptoms such as fatigue, weakness and shortness of breath may occur.16, 20 However, some cases can remain asymptomatic.21 Untreated ID, particularly IDA, leads to reduced cognitive function,22 decreased work productivity and diminished overall quality of life.4, 21, 23 During pregnancy, untreated ID hampers fetal brain maturation and development,2, 21, 24 and contributes to low birth weight and maternal complications.19 Untreated ID can also affect child development, causing impaired school performance.2 Addressing ID and IDA could yield substantial economic returns.25

Diagnosing and managing ID and IDA present challenges due to varying diagnostic criteria and tests.19 Haemoglobin concentration lacks sensitivity and specificity, leading to potential underestimation of ID.14 ID without anaemia can be elusive, with vague symptoms, necessitating investigation in patients with normal complete blood counts and low ferritin levels.19, 21 Conditions like pregnancy, thalassaemia and inflammatory disorders can complicate diagnosis by impacting ferritin levels.20 Inconsistent laboratory reference ranges for ferritin in women further hinder accurate diagnosis.19 Striking a balance between diagnostic thresholds is crucial, as setting it too low risks overlooking iron deficiency cases.19 Comprehensive guidelines for early detection and management are essential, especially among women of childbearing age.19 Implementing effective screening practices, including measuring ferritin and haemoglobin levels, can enhance outcomes and alleviate the associated health burdens.19

1.4 FIP contribution to support pharmacists’ roles in managing anaemia

Historical efforts have often emphasised iron deficiency as the primary cause of anaemia; however, the complexity of anaemia demands a multifaceted approach.26 A collaborative approach involving various stakeholders, including
governments, civil society, healthcare professionals, academia, researchers and the media, is essential to drive meaningful progress. Each plays a specific role in reducing anaemia and promoting good health. Associations and societies of healthcare professionals can promote education and awareness among association and society members, professionals and the general public about the importance of addressing anaemia comprehensively.  

The International Pharmaceutical Federation (FIP), a global professional leadership body for pharmacists, pharmaceutical scientists and educators, conducted an exploration study in May 2022 on pharmacists’ role in anaemia, specifically IDA. This study underscored the imperative of enhancing the involvement of practising pharmacists, particularly community and hospital pharmacists, in IDA management. With a foundation in clinical expertise and a widespread presence, pharmacists possess substantial opportunities to play a pivotal role in reducing IDA. This encompasses diverse aspects, including understanding the causes, participating in treatment strategies, engaging in preventive measures and promoting self-care practices.

This explorative study also highlights the necessity to offer educational assistance to pharmacists, achieved through the provision of guidelines or toolkits for anaemia counselling, treatment, management, screening and prevention, complemented by comprehensive training sessions and workshops. It is recommended that national professional leadership bodies collaborate in developing practice support materials. These resources would empower pharmacists to excel in their role, ultimately contributing to the advancement of public health through comprehensive anaemia management strategies.

1.5 Handbook development to support pharmacists’ roles in IDA

This handbook is designed to be a valuable resource for a range of stakeholders:

- **Pharmacists** — This handbook serves as a comprehensive guide for pharmacists, offering guidance on screening, treating, managing, and preventing iron deficiency anaemia. It equips pharmacists with the knowledge and skills necessary for tasks like screening and counselling, enabling them to provide personalised patient care and stay updated on the latest guidelines and treatments.

- **Professional pharmacy leadership bodies** — Professional leadership bodies can share this handbook with their members to enhance their practice and improve patient care.

- **Pharmacy students** — Pharmacy students can use this handbook as a foundational resource to build their understanding of IDA.

- **Researchers and academics** — This handbook can serve as a valuable reference source for researchers and academics studying IDA, helping them identify and address research gaps in this field.
This handbook consists of seven sections (Figure 2).

**Figure 2: Sections included in this handbook**

- **Section 1**: Introduction
- **Section 2**: Role of pharmacists in IDA
  - Includes the role of pharmacists in IDA, self-care support, and the skills and knowledge needed for IDA management
- **Section 3**: IDA management in adults
  - Includes both pharmacological and non-pharmacological interventions for IDA, guidelines for administering treatment, managing side effects, and monitoring progress. It also provides patient counselling guide points
- **Section 4**: IDA management in special populations
  - Includes the IDA management in pregnant and breastfeeding mothers, paediatrics, geriatric patients, chronic disease patients, and those with strict diets or bleeding patients
- **Section 5**: IDA prevention
  - Includes public education, awareness raising, identification of high-risk individuals, preventive measures to increase iron intakes, monitoring and evaluation
- **Section 6**: Summary and conclusions
  - Conclusion: Summarising key findings and providing recommendations for future work
- **Section 7**: References
2 Role of pharmacists in IDA

2.1 Pharmacists’ roles in supporting self-care with regard to IDA

Pharmacists play a pivotal role in advancing self-care practices, including addressing IDA. Defined by the WHO as individuals’ ability to manage their health independently, self-care is vital to improving well-being and achieving universal health coverage. Empowering patients to actively participate in their health management enhances patient-centred care and overall healthcare outcomes. Self-care should not be confused with self-medication. Self-medication involves using medication to treat self-diagnosed disorders or symptoms or the intermittent or continued use of prescribed medicines for chronic or recurrent conditions. Self-care empowers individuals to make informed health choices, and pharmacists, easily accessible healthcare professionals, can support individuals in making informed decisions on their health. Pharmacists are crucial in advocating and facilitating self-care, offering various interventions to enhance patient autonomy. They act as promoters, supporters and overseers of self-care within their communities and can contribute as programme managers and policymakers. Pharmacists’ involvement in self-care helps address health system challenges, such as limited access to healthcare, poor health literacy and financial barriers, ultimately benefiting individuals and communities in managing conditions like IDA.

The Global Self-Care Federation established the Self-Care Readiness Index in 2021 and updated the index in 2022. It serves as a comprehensive framework for implementing self-care and a powerful advocacy tool for elevating self-care’s status in local and international contexts. This framework spotlights four critical enablers of self-care: stakeholder support and adoption, consumer and patient empowerment, self-care health policies, and a supportive regulatory environment. Pharmacists play an essential role in advancing the second enabler, consumer and patient empowerment, as they engage with patients directly, empowering them to make well-informed health choices, particularly in managing conditions such as IDA. This aligns with the index’s recommendations to enhance the availability of quality self-care information and encourage healthcare providers, including pharmacists, to endorse self-care practices, especially in the context of IDA prevention, screening and management. Furthermore, the call for interprofessional collaboration resonates with the need for a coordinated approach to address IDA through self-care, ensuring the optimal delivery of information and services to patients facing this specific health challenge. The Self-Care Readiness Index, in conjunction with pharmacists’ role, underscores their significant contribution to promoting self-care practices in the context of IDA and other health concerns.

The seven pillars framework of self-care is also relevant in addressing IDA, for which it offers a comprehensive structure for individuals to bolster their self-care abilities. Firstly, within the “Knowledge and health literacy” pillar, pharmacists empower individuals by providing crucial information about IDA, its underlying causes and the available treatment options, enabling patients to make well-informed decisions tailored to their specific needs. They significantly contribute to the “Healthy eating” pillar by offering dietary guidance, emphasising the importance of incorporating iron-rich foods and supplements into the diet, which is especially pertinent for individuals managing IDA. Furthermore, in the “Rational use of products and services” pillar, pharmacists play a central role in ensuring the responsible and effective use of iron supplements, offering expert advice on proper dosage and timing, crucial considerations for those dealing with IDA. Additionally, they actively support the “Risk avoidance and mitigation” pillar by counselling patients on lifestyle modifications to prevent the recurrence of anaemia, such as addressing dietary deficiencies and advocating behaviours that mitigate risks. In essence, by actively engaging with patients and applying their expertise, pharmacists bridge the gap between the seven pillars framework and effective self-care practices, providing invaluable guidance for individuals managing the complexities of IDA and ultimately contributing to improved health and quality of life.

The self-care matrix (SCM) is another valuable framework that pharmacists can leverage to enhance their role in addressing IDA. The SCM encompasses the various facets of self-care, acknowledging the influence of social and health systems, environmental factors and policy-based determinants on individuals’ self-care practices. Pharmacists equipped with an understanding of this framework can better support patients in maximising their autonomy and advocating person-centred decision-making when managing conditions like IDA. The SCM offers pharmacists a holistic perspective to comprehend the complex factors influencing self-care. Specifically, pharmacists can align their interventions with the SCM’s dimensions to empower patients with knowledge about IDA, foster self-awareness regarding its management, promote physical activity and healthy eating, and advise on risk avoidance and mitigation strategies. Furthermore, the SCM highlights the importance of considering external support and resources, making
pharmacists pivotal in organising educational sessions or workshops to cater to individual needs. Additionally, in the realm of the self-care environment, pharmacists can advocate policy changes and community engagement initiatives to improve access to resources and healthcare services. By aligning their practices with the SCM’s cardinal dimensions, pharmacists can enhance their role in improving individuals’ health literacy in IDA, ensuring a comprehensive and effective approach to self-care in this context.29, 38

2.2 Pharmacists’ roles in managing IDA across practice sectors

Pharmacists are well-trained to effectively educate patients and provide evidence-based advice on a broad range of topics, including self-care interventions and the use of non-prescription medicines or supplements in IDA.29, 39 With their expertise, pharmacists can actively engage patients in discussions about IDA, explaining the importance of iron supplements and addressing any concerns or misconceptions. FIP has recently introduced toolkits for medication review and reconciliation to support pharmacists in improving medication adherence and health outcomes.40 As pharmacists actively contribute to better medication management, they empower individuals to navigate IDA with confidence and competence, promoting a holistic approach to self-care and ultimately mitigating the impact of this condition on overall health and well-being. By fostering health literacy and advocating medication adherence, pharmacists play a pivotal role in supporting individuals on their journey to manage IDA and achieve optimal health outcomes effectively.41 The increasing role of pharmacists in the healthcare system, coupled with being the most accessible members of the health workforce,42-44 enable them to contribute significantly to the management of conditions such as IDA.28

In a community setting, pharmacists can provide health services and information on preventing and managing IDA.45 Several studies have documented the role of pharmacists in IDA in community settings. A study carried out in Peru examined the feasibility and acceptability of training the pharmacy workforce to offer point-of-care testing for chronic diseases, including anaemia. It was reported that nearly 100% of 371 clients preferred the pharmacy for point-of-care testing due to better access, faster results, and faster and better attention. This study underscored the unique role of pharmacists in providing point-of-care testing services in the community setting. It also highlighted an opportunity to train the pharmacy workforce to conduct early detection and screening of the disease.46 In Tanzania, a study revealed that private pharmacies were in closer proximity and offered greater convenience than government clinics, indicating the potential contributions of pharmacists in supporting maternal iron supplementation in rural areas.47 This study recommended the importance of educating the public about the existing policies and treatments for anaemia, a role in which pharmacists actively participate by providing health education to the public and society.48

In a hospital setting, pharmacists can optimise patient outcomes by monitoring and adjusting treatment plans.49 Studies in Jordan50 and Thailand51 explored how clinical pharmacist interventions in an outpatient clinic in a hospital improved patients’ outcomes through pharmaceutical care programmes, such as providing comprehensive patient counselling for those with IDA.50, 51 Pharmacists’ evolving roles include their ability to prescribe,52, 53 initiate or discontinue specific medicines, adjust the dosage52-54 and order relevant laboratory tests.52, 53, 55, 56 Additionally, they are also actively involved in developing evidence-based practice guidelines in collaboration with fellow healthcare professionals.54, 56, 57 Pharmacists are strategically positioned to influence drug formulary choices and healthcare management, thereby promoting adherence to guidelines and reducing costs tied to specific medicines.52, 57 Their active engagement in providing health advice was proven to yield significant therapeutic impact and garnered approval from fellow healthcare professionals.56, 58

In addition to the role of community and hospital pharmacists, researchers in the field of pharmacy also play a significant role in addressing IDA alongside researchers from other fields. Their involvement in IDA research aligns with the broader goals of understanding, managing, and raising awareness of this condition. Pharmacy researchers contribute to understanding IDA’s pathophysiology and its implications for medication management. Their research often intersects with areas such as pharmacokinetics and pharmacodynamics of different iron formulations, including exploring optimal dosing regimens and evaluating the safety and effectiveness of treatment options for IDA. Furthermore, they actively engage in clinical trials to assess the efficacy and tolerability of oral and intravenous iron supplements, focusing on patient adherence and outcomes. This research directly informs evidence-based guidelines for IDA treatment, ensuring that pharmacists and healthcare providers can offer the best possible care to patients. Their dissemination of research findings through publications, conferences and workshops can contribute to the body of knowledge on IDA, promoting best practices and ensuring access to appropriate iron repletion therapies.
The exploratory study conducted by FIP in May 2022 highlighted various roles of pharmacists in anaemia management, which include screening and detection, medication management, patient counselling and monitoring patient progress. The conversation specifically underscored the pharmacist’s role in taking patients’ medical histories and ensuring the appropriate selection of supplements based on dietary habits and over-the-counter medicines. The participants also highlighted the need for guidelines or toolkits, along with subsequent training or workshops, to improve their competence in the management of IDA. A key enabler identified in this study was collaboration with other healthcare professionals, which is particularly pertinent to the development of community-based, point-of-care testing. Based on the findings in this study, it is evident that there is an increasing opportunity for pharmacists to contribute to the attainment of the WHO’s global anaemia target, particularly through early detection, medication management and delivering health education to both individual patients and the broader community.  

2.3 Educational needs to support pharmacists’ role in IDA

Roundtable participants of the exploratory study conducted by FIP in May 2022 shared a variety of competencies needed to support pharmacists’ role in IDA. The insights shared during this discussion are represented in Figure 3.

Specifically, regarding patient education and counselling, participants emphasised two key qualities that pharmacists should possess: confidence in patient management and effective communication skills. Furthermore, a strong foundational knowledge of IDA, as detailed in Figure 4, was identified as crucial to enhance their proficiency in this domain.

An important suggestion from this roundtable was the need to develop a comprehensive guideline, toolkits or handbook tailored to individual pharmacists, addressing the topic of IDA. These resources would function as educational manuals, providing guidance on patient screening and counselling and encompassing critical information such as:

- Anaemia causes and pathophysiology
- Anaemia therapy and monitoring
- Pharmacokinetics, pharmacodynamics, bioavailability of iron supplements
- Interaction of iron supplements and therapeutic choices
- Dietary recommendations and healthy lifestyles

Figure 3: Competencies needed to support pharmacists’ role in IDA

Figure 4. Knowledge that pharmacists should have related to IDA

An important suggestion from this roundtable was the need to develop a comprehensive guideline, toolkits or handbook tailored to individual pharmacists, addressing the topic of IDA. These resources would function as educational manuals, providing guidance on patient screening and counselling and encompassing critical information such as:
• Diagnosis and severity assessment of anaemia;
• Appropriate medication selection, including details on iron preparations, their bioavailability, and pharmacokinetics to aid in supplement choice and formulation decisions;
• Common side effects associated with medicines and supplements; and
• Dietary guidelines to complement treatment strategies.

In addition to these resources, participants also recommended the establishment of professional programmes designed to enhance pharmacists’ competence in managing IDA. These programmes could include workshops, self-directed learning opportunities, or continuing professional development courses, all centred around anaemia-related knowledge and skills. Collaboration with national professional leadership bodies would facilitate the organisation of workshops and self-directed learning initiatives, and the sharing of best practices.27, 28

The handbook serves as an invaluable resource, providing pharmacists, specifically in patient-facing roles, with the essential knowledge needed to address the identified gaps above in their understanding of IDA.
3 IDA management in adults

3.1 Identification and investigation of IDA

Early identification is pivotal in effectively managing IDA, and pharmacists can play a role in this process. They can support detecting potential cases, assessing patients’ symptoms and signs, reviewing medical and medication histories, recommending additional tests and making referrals when necessary. This proactive approach can occur in various healthcare settings, including community pharmacies, hospitals and primary healthcare centres.

3.1.1 Signs and symptoms

In community or primary healthcare settings, pharmacists can support identifying common signs and symptoms of ID, with or without anaemia, such as fatigue and weakness, pale skin, dizziness, shortness of breath, fast or irregular heartbeat, strange cravings to eat items that are not food, a tingling or crawling feeling in the legs, cold hands and feet, tongue swelling or soreness, brittle nails, and headache. By asking targeted questions during patient interactions, pharmacists can pick up on these symptoms and suggest further testing if necessary (see Figure 5).

Figure 5: Questions that pharmacists can ask to identify the common signs and symptoms of IDA:

- Have you been feeling unusually tired or fatigued lately?
- Do you often feel weak or find it difficult to perform routine tasks?
- Have you noticed that your skin appears paler than usual?
- Do you experience shortness of breath, especially after physical activity?
- Have you noticed any changes in your nails, such as brittleness or spooning (concave shape)?
- Do you often feel dizzy or lightheaded?
- Have you experienced any unusual cravings, such as a desire to eat ice, dirt or starch?
- Have you noticed any changes in your appetite or weight?

3.1.2 Medical and medication histories

Examining medical and medication histories helps tailor the treatment according to the cause and severity of iron deficiency. A comprehensive history-taking approach facilitates accurate diagnosis and guides appropriate management of IDA. Some key aspects to be considered are blood donation history, previous history of IDA, dietary intake, overt blood loss and haemoglobinopathies. Additionally, conducting a thorough medication history is crucial, particularly the use of NSAIDs or anticoagulants. Individuals with underlying conditions leading to IDA should either be treated or referred to a specialist, such as a gastroenterologist or a gynaecologist, for comprehensive care.

3.1.3 Examination and investigation

Some key aspects of examination include pallor assessment (conjunctiva, mucous membranes, nail), vital signs (blood pressure, heart rate and respiratory rate), cardiovascular examinations (heart murmurs), respiratory assessment (shortness of breath), skin and hair changes (koilonychia, dryness) and evaluation of oral cavity.

Some diagnostic tests contribute to the confirmation of IDA:

- **Serum haemoglobin** — Anaemia is defined as follows: Hb<13 g/dl (men aged over 15 years), Hb<12 g/dl (non-pregnant women aged over 15 years and children aged 12–14 years of age).
- **Red cell indices** — A mean corpuscular volume (MCV) less than 95 femtolitres has a sensitivity of 97.6% for iron deficiency anaemia. Other red blood cell changes associated with iron deficiency include reduced mean...
Iron deficiency anaemia: Managing symptoms and supporting self-care

cell Hb (MCH) — hypochromia, increased percentage of hypochromic red cells, anisocytosis (variation in the size of red blood cells), and poikilocytosis (presence of irregularly shaped red blood cells) 69

- **Serum ferritin levels** — Serum ferritin is the primary test to diagnose absolute iron deficiency for patients without inflammation.70 While a ferritin level of ≤15 microgram/l was traditionally used for iron deficiency diagnosis in adults, a newer approach suggests a threshold of ≤30 microgram/l, providing 92% sensitivity and 98% specificity, which is now commonly used.

- **Transferrin saturation (TSAT)** — TSAT is not influenced by chronic inflammation as is the case with ferritin and is an important arbiter of iron status, especially in the face of chronic inflammation. A TSAT of <20% is indicative of IDA.59, 71

- **Hepcidin level** — Hepcidin level is decreased (<6 ng/ml) or normal (6–46 ng/l) in IDA,72 but this can be affected by factors such as circadian rhythm and hepatic and renal function. Hepcidin assessment can be useful to confirm Iron Refractory Iron Deficiency Anemia (IRIDA), but this assessment is not routinely or widely used in clinical practice.67, 72

- **Reticulocyte haemoglobin (RetHe)** — Combining hepcidin and reticulocyte haemoglobin levels can effectively differentiate between IDA and anaemia of chronic disease. When hepcidin levels are within the normal range, and RetHe is less than 30 pg, it suggests the presence of IDA.72 Reticulocyte haemoglobin is accurate but frequently not accessible for many practitioners and patients.

Recognising that the accessibility of advanced tests can be a challenge for rural areas in certain nations, where such tests may not always be easily obtainable or affordable, it becomes imperative to explore alternative, cost-effective approaches for rural healthcare. Pharmacists should be vigilant in aligning their practices with the national guidelines regarding commonly employed diagnostic tests for IDA within their respective countries.

In some countries and facilities, pharmacists can conduct initial screening tests for anaemia, such as point-of-care testing for haemoglobin or iron level test. These tests are quick, easy to perform, and provide immediate results, enabling pharmacists to identify potential cases of IDA during a routine pharmacy visit. Some general steps on how to perform a point-of-care haemoglobin test are outlined in Figure 6.

1. **Prepare the patient:** Explain the procedure to the patient and ensure they are comfortable. Clean the area where the blood sample will be taken (usually a fingertip or a vein in the arm) with an alcohol swab.

2. **Collect the sample:** For a haemoglobin test, a sample of blood is taken by pricking the fingertip or inserting a needle into a vein in the patient’s arm. For infants, the sample may be obtained by pricking the heel.

3. **Perform the test:** Apply the blood sample to the test strip or cuvette of the point-of-care testing device. Ensure that the sample adequately fills the required area.

4. **Analyse the results:** Insert the test strip or cuvette into the device and wait for it to process. The device will display a haemoglobin measurement.

5. **Interpret the results:** Compare the patient’s haemoglobin level with reference ranges provided by the device manufacturer or relevant health guidelines.

6. **Document and communicate:** Record the results in the patient’s health record and communicate them to the patient and their healthcare provider.

Figure 6: General steps on how to perform a point-of-care haemoglobin test73
3.1.4 Referrals

If the point-of-care test results or the presence of signs and symptoms suggest IDA, pharmacists can refer patients to a general practitioner, a gynaecologist or a specialist for further testing and diagnosis. This ensures that patients receive appropriate medical attention in a timely manner. Treating underlying causes of IDA is also critical, and pharmacists are advised to consult a general practitioner, a gynaecologist or a specialist. Interprofessional collaborative approaches are important in IDA management.

It is important to note that the scope of pharmacy practice in some countries may vary, and pharmacists need to refer patients directly to a general practitioner, a gynaecologist or other specialist for further evaluation before initiating treatment. Therefore, pharmacists are advised to follow national guidelines regarding their roles in screening, including the availability of point-of-care testing in pharmacy.
Figure 7 is a flowchart to guide pharmacists in identifying patients with suspected IDA in a community pharmacy or a primary healthcare setting.

A patient presenting with possible symptom of iron deficiency to a pharmacy, such as tiredness and lack of energy, fatigue, weakness, pale skin, noticeable heartbeats (heart palpitations), dizziness, shortness of breath, problem thinking, cold hands and feet, or wanting to eat non-food items (for example, paper or ice).

Gather a detailed patient’s history.
- Does the patient belong to vulnerable groups?
  - How is their dietary intake?
  - What is their medication history?
- Family history related to anaemia or other disorders?
- Any medical history related to anaemia or other disorders?
- Any history of blood donation?
- Any travel history to place with increased risk of hookworm or schistosomiasis?

Assess signs.
- If your pharmacy has infrastructure or authority to conduct patients’ examination, you may conduct pallor assessment (conjunctions, mucous membranes, nail), vital signs (blood pressure, heart rate and respiratory rate), cardiovascular examinations (heart murmurs), respiratory assessment (shortness of breath), ulceration of the corners of the mouth, spoon-shaped nails, dry and damaged hair.

Arrange necessary investigations.
- For patients with suspected IDA, arrange a full blood count.
- If your pharmacy has infrastructure for a point of care testing, haemoglobin or iron level test can be offered to the patient via prick blood spot test or any other tests available in the pharmacy. If you have a collaboration with any diagnostic laboratory, refer patient for further testing.

Educate the patient.
- Educate patients with appropriate therapy, such as oral iron supplementation or IV iron (if appropriate), and nonpharmacological treatment for IDA. See Section 3.4.1 Patient counselling guide points for educating the patient.

*Paediatrics, non-pregnant women of reproductive age (check patients’ period and possible heavy menstrual bleeding condition), pregnant women and breastfeeding mothers, geriatric and chronic disease patients, patients with chronic blood loss. See Section 4 IDA management in special populations.
*Check if patients are in dietary restriction, such as vegan or vegetarian to identify poor iron intake.
*Check if patients take any medications which could affect iron metabolism, such as aspirin, NSAID, proton pump inhibitors, anticoagulants, corticosteroids.
*Check if patients have family history such as IDA (may indicate inherited disorders), bleeding, gastrointestinal and haematological disorders.
*Check if patients have medical history related to anaemia, such as gastrointestinal bleeding or bypass surgery of gastrointestinal tract.

*If patients belong to vulnerable groups, you may provide oral iron supplements according to the authority in your countries and you may provide counselling guided by the patient’s history. See Section 3.4.1 Patient counselling guide points.
*If the patient has a history of low dietary intake, provide some counselling on non-pharmacological approaches, and sources of iron-rich food. See Section 3.3 Nonpharmacological treatment for more information.

Figure 7: Flowchart to guide pharmacists in identifying patients with suspected IDA in a community pharmacy or primary healthcare setting

15, 59-62, 67, 69, 73-76
3.2 Pharmacological treatments

3.2.1 Iron repletion therapy

Iron repletion therapy involves iron administration orally and parenterally (such as intravenous, intramuscular (not common in practice) or intradialytic (specific for patients with chronic kidney disease). The decision-making process between these options involves considering factors such as underlying cause, symptoms severity, therapy objectives, response to prior therapy, desired pace of haematological improvement, patient preference, cost and accessibility to treatment.63, 77

3.2.1.1 Oral iron

Oral iron is commonly regarded as the first-line treatment option due to its affordability and widespread availability compared with intravenous iron (IV iron). While it is generally effective, in cases where oral iron is not properly tolerated or certain medical conditions are present, IV iron may be required.78

Dosing regimen and iron-containing preparations

The conventional therapeutic approach involving high dose iron supplementation has been demonstrated to increase hepcidin levels and reduce iron bioavailability, especially when taken multiple times a day.79 The initial recommended dose of oral iron in adults is 100–200 mg elemental iron once daily or in two or three divided doses. However, there is growing evidence supporting the efficacy of lower daily doses,80, 81 which are found to have fewer gastrointestinal side effects. If patients exhibit poor tolerance to oral iron supplementation, it is advisable to use a lower dose, intermittent dosing schedules or try different formulations.82 This therapeutic dose is determined by the severity of symptoms, patients’ ferritin levels, their age and adverse gastrointestinal reactions.83

There is a wide range of iron-containing preparations available in the market. They vary in terms of dosage, type of iron salt and whether the iron is present in its ferrous or ferric form.84 The ferrous form of iron (Fe²⁺) found in the most widely used iron supplements is preferred due to its higher solubility, resulting in higher bioavailability in dietary supplements than ferric iron (Fe³⁺).85 There are several oral iron preparations available for the treatment of anaemia, as shown in Table 1.

Table 1: Common doses and elemental iron content of available oral iron formulations

<table>
<thead>
<tr>
<th>Form</th>
<th>Formulation</th>
<th>Elemental iron</th>
<th>Adult dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrous fumarate*</td>
<td>325mg tablet</td>
<td>106mg (33%)</td>
<td>One tablet, once per day or once every other day</td>
</tr>
<tr>
<td>Ferrous gluconate*</td>
<td>325mg tablet</td>
<td>38mg (12%)</td>
<td>One to three tablets, once per day or once every other day</td>
</tr>
<tr>
<td>Ferrous sulfate*</td>
<td>325mg tablet</td>
<td>6mg (20%)</td>
<td>One to two tablets, once per day or once every other day</td>
</tr>
<tr>
<td>Haem iron polypeptide</td>
<td>398mg tablet</td>
<td>11 mg</td>
<td>One to three tablets per day</td>
</tr>
<tr>
<td>Polysaccharide iron complex</td>
<td>150mg tablet</td>
<td>150mg</td>
<td>One tablet, once per day</td>
</tr>
<tr>
<td>Ferric citrate</td>
<td>1,000mg tablet</td>
<td>210mg</td>
<td>One tablet, once every other day</td>
</tr>
</tbody>
</table>

*Three commonly administered types of ferrous iron supplements.85, 86 They vary in the content of absorbable elemental iron, but some studies suggested that these iron preparations are roughly equivalent in bioavailability.87-89

The list of examples and doses in this table is not exhaustive. There are also liquid formulations available.90

For the initial treatment of IDA, the British Society of Gastroenterology recommends taking one tablet of oral iron daily, containing ferrous sulfate, fumarate or gluconate.92 This is attributed to their affordability, acceptable tolerability, good bioavailability, high efficacy, and availability in different formulations in correcting anaemia and restoring iron stores.60, 84 A recent review of 111 studies involving 10,695 participants looking at different oral iron preparations indicated that slow-release ferrous sulfate is more tolerable than conventional immediate-release ferrous iron salts.91 Additional common types of iron formulations include ferrous ascorbate, ferrous succinate, carbonyl iron, ferric citrate, liposomal iron, haem iron polypeptide and polysaccharide iron complexes.93
Iron deficiency anaemia: Managing symptoms and supporting self-care

Pharmacokinetic properties of oral iron
Bioavailability of iron depends on several factors, including the form of iron administered (with the ferrous form being more easily absorbed), the dosage, the level of erythropoiesis, dietary intake and existing iron reserves. The absorption of iron in the gastrointestinal tract increases in individuals with iron deficiency. The oral bioavailability of iron can range from less than 1% to over 50%, and one of the factors influencing the absorption of iron is the quantity of iron stored in the body. Taking iron alongside meals can also reduce the bioavailability of oral iron by up to 75%. This implies that iron should be taken during fasting or in intervals between meals throughout the day.

Certain compounds found in foods, such as phytate in whole grains and calcium in milk, can hinder iron absorption. In addition to phytate and calcium, phenolic compounds, including phenolic monomers and polyphenols (tannic acid and tannins), also hinder iron absorption through a complex formation of chelates with iron in the gastrointestinal lumen. Polyphenols are particularly abundant in tea, coffee, cocoa, red wine and some herbal teas. Drinking a cup of tea resulted in a 64% decrease in iron absorption from a test meal, whereas drinking a cup of coffee led to a reduction of 39%. The inhibitory effect of tea on iron absorption disappears within an hour.

Vitamin C may improve iron absorption by exerting its iron-reducing and chelating effects. Some studies have shown that this may not be clinically effective at enhancing iron absorption, but many national guidelines recommend consuming iron in food or supplements with foods or drinks containing vitamin C, while avoiding substances that inhibit iron inhibitors is recommended. Vitamin C can counteract and abolish the inhibitory effect of polyphenols on iron absorption, indicating that ascorbic acid has a higher affinity to iron than polyphenols.

Commonly prescribed medicines, including proton pump inhibitors and histamine-2 receptor antagonists, can impede iron absorption. Gastric acid plays a vital role in aiding the absorption of non-haem iron. It accomplishes this by releasing iron from food particles and converting it from the less absorbable ferrous form to the more easily absorbed ferric form. Hence, PPIs and histamine-2-receptor antagonists that suppress gastric acid production can impair iron absorption. Other medicines that may interact with iron are tetracyclines, where there is a pharmacokinetic interaction (decreased oral absorption of both iron and tetracyclines), and thyroid agents where there is possible pharmacokinetic interaction (decreased thyroxine absorption).

Numerous underlying medical and surgical conditions can lead to impaired iron absorption. These include inflammatory bowel disease, coeliac disease, chronic pancreatitis, Helicobacter pylori infection, gastrectomy, gastric bypass and small bowel resection. Patients with persistent gastrointestinal or gynaecologic bleeding or other forms of blood loss might find it challenging to absorb adequate enteral iron to counterbalance these losses, even when absorption is not impaired. In situations where oral iron therapy alone proves insufficient or ineffective, exploring alternative approaches is crucial.

Side effects of oral iron
Common side effects that pharmacists should communicate to patients include:

- **Gastrointestinal issues** — Gastrointestinal side effects associated with oral iron repletion therapy are very common, often leading to non-adherence in up to 50% of patients. This can result in treatment discontinuation and, consequently, inadequate therapeutic outcomes. The issues can include constipation, diarrhoea and stomach upset, such as stomach cramps, nausea or vomiting. While it is better to take oral iron on an empty stomach, with the presence of gastrointestinal side effects, it is sometimes recommended to take oral iron with meals.
- **Dark stools** — Iron supplements can make the stool black or dark green. This is generally harmless and should not be a cause for concern.
- **Metallic taste** — Some people may experience a metallic taste after taking iron supplements.
- **Teeth staining** — Liquid iron formulations, such as ferrous sulfate drops, syrups, elixirs and suspensions, may cause teeth staining.
- **Other side effects** — Less common side effects can include fainting, dizziness, chest pain and fast heartbeat.
Iron deficiency anaemia: Managing symptoms and supporting self-care

Treatment duration and monitoring parameters

The goal of oral iron treatment is to increase haemoglobin levels by 2 g/dl within four weeks. An increase of 1 g/dl in haemoglobin levels following one month of treatment is considered an adequate response to therapy. For adults, treatment should be continued for three months after the anaemia is corrected to ensure the replenishment of iron stores. The correction of anaemia should be confirmed by normalisation of ferritin levels or TSAT.

3.2.1.2 Parenteral iron

Parenteral iron can be administered intravenously, intramuscularly or intradialytically.

IV iron is a rapid and effective treatment for IDA, offering advantages over oral therapy and blood transfusion. The main advantage of IV iron lies in its capacity to bypass the gastrointestinal tract, reducing mucosal irritation and related side effects. Additionally, healthcare providers have confidence in patient adherence. IV iron has demonstrated higher efficacy than oral iron and is generally better tolerated. However, its widespread use is constrained by availability and cost considerations.

The use of intramuscular (IM) iron therapy for iron repletion is generally discouraged in current recommendations. This is because IM iron is poorly absorbed, no safer than IV iron therapy, and can result in local side effects such as pain and skin discoloration at the injection site. However, it is important to note that there are specific clinical scenarios where IM iron therapy might still be appropriate, and these decisions should be made based on clinical judgement.

Intradialytic treatment refers to administering iron therapy during haemodialysis sessions. Intradialytic iron supplementation using ferric pyrophosphate citrate was demonstrated to maintain haemoglobin levels safely, reduce the need for erythropoiesis-stimulating agents, and to help manage anaemia in patients with chronic kidney disease who are undergoing haemodialysis.

When to treat patients with IV iron

IV iron administration should be considered for patients with one or more of the following:

- Demonstrated intolerance, poor adherence or lack of efficacy with oral iron due to gastrointestinal side effects despite modification of dose, timing and frequency.
- Pregnancy beyond the first trimester with haemoglobin levels below 10.5 g/dl, at which oral iron is unlikely to provide sufficient iron for fetal development.
- Iron deficiency with severe anaemia (e.g. Hb<7 g/dl) and stable haemodynamics, while severe anaemia with organ ischaemia is treated with transfusion.
- Presence of comorbidities interfering with oral iron absorption (e.g., inflammatory bowel disease, chronic renal impairment).
- There is inadequate time for oral iron to achieve a suitable response when surgery is imminent.
- Ongoing blood loss surpassing the capacity of oral iron absorptive to meet needs (heavy menstrual bleeding, mucosal telangiectasias).
- Malabsorption syndromes (coeliac disease, Whipple’s disease, bacterial overgrowth), which potentially compromise iron absorption.

Studies suggested that IV iron is not necessarily associated with acute and chronic infection risk. A prospective study involving 988 patients undergoing haemodialysis across 19 European centres, followed over six months with 51 episodes of bacteraemia, revealed no association between IV iron and the risk of infection. Infection should not be seen as a contraindication to intravenous iron repletion therapy if a careful evaluation of the risk/benefit supports the treatment of the anaemia.

Dosing regimen and IV iron preparations

A range of IV iron preparations is available, and the selection of which formulation to use depends on several factors, including cost considerations, the preference of the patient and physician, and the product’s availability. Older IV iron
formulation, such as high-molecular-weight dextran iron, has been withdrawn due to their unfavourable safety records, characterised by a relatively high incidence of anaphylactic reactions.\textsuperscript{125}

Concerning the dosing regimen, a formulation with a smaller dose would be more suitable for patients who have frequent hospital visits, such as individuals undergoing haemodialysis due to chronic kidney disease. On the other hand, larger-dose preparations are more convenient for patients who require rapid iron replenishment. Furthermore, there can be variations in how well different patients tolerate certain formulations.\textsuperscript{63} Table 2 provides a list of parenteral iron formulations.

### Table 2: Parenteral iron formulations available in the market\textsuperscript{63}

<table>
<thead>
<tr>
<th>Compound</th>
<th>Concentration of elemental iron</th>
<th>Recommended amount per dose\textsuperscript{a}</th>
<th>Infusion time\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-molecular-weight iron dextran (LMW ID)\textsuperscript{c}</td>
<td>50mg/ml</td>
<td>Single dose of 1,000mg (diluted in 250ml normal saline) or multiple doses of 100mg.</td>
<td>2–6h</td>
</tr>
<tr>
<td>Ferrous gluconate (FG)</td>
<td>12.5mg/ml</td>
<td>Multiple doses of 125 to 250mg.</td>
<td>12.5mg/min</td>
</tr>
<tr>
<td>Iron sucrose (also referred to as iron saccharate)</td>
<td>20mg/ml</td>
<td>Multiple doses of 200 to 300mg. Typically ranging from 1 to 3 weeks.\textsuperscript{126}</td>
<td>100mg/30min</td>
</tr>
<tr>
<td>Ferumoxytol</td>
<td>30mg/ml</td>
<td>Single dose of 1,020mg or 2 doses of 510mg, given 3 to 8 days apart.</td>
<td>15min</td>
</tr>
<tr>
<td>Ferric carboxymaltose\textsuperscript{d}</td>
<td>50mg/ml</td>
<td>For weight ≥50kg: 1 or 2 doses of 750mg, administered at least 7 days apart. For weight &lt;50kg: 1 or 2 doses of 15mg/kg, administered at least 7 days apart.</td>
<td>15min</td>
</tr>
<tr>
<td>Ferric derisomaltose (previously called iron isomaltoside)</td>
<td>100mg/ml</td>
<td>For weight ≥50kg: A single 1,000mg dose or up to 3 doses of 500mg, administered over 7 days For weight &lt;50kg: A single dose of 20mg/kg</td>
<td>Infusion time ranges between &gt;15min and ≥30min</td>
</tr>
</tbody>
</table>

\textsuperscript{a} A 25mg test dose before infusion of a full dose of iron dextran is required; test doses are not required with the other agents but are often recommended in patients with multiple drug allergies or a history of prior reactions to IV iron.\textsuperscript{127}

\textsuperscript{b} The infusion time depends on the dose and whether it is being administered in a diluted or undiluted form. Refer to the updated drug product inserts for specific guidance.

\textsuperscript{c} High molecular weight iron dextran (HMW ID) is no longer available. LMW ID can be administered intramuscularly; however, it is considered painful and less effective than intravenously.

\textsuperscript{d} There are some advantages of this iron preparation compared to other available iron formulations; however, this preparation is the most expensive preparation and inaccessible for many patients. Pharmacists need to consider cost-effectiveness in advising the treatment.

All these preparations, as listed in Table 2, are equally effective in managing iron deficiency and share a similar safety profile.\textsuperscript{105, 128, 129} Some key differences include cost, formulary agreements, procurement agreements, the frequency of visits or time needed to administer the full dose.\textsuperscript{64} Healthcare professionals are advised to refer to the product monographs, as certain formulations recommend weight-based dosing.\textsuperscript{63, 64}
**Pharmacokinetic properties**

Iron is administered intravenously as iron carbohydrate complexes, composed of polynuclear iron(III)-hydroxide surrounded by the carbohydrate ligand. The ligand aims to stabilise the complex and protect it against further polynuclearisation. Some pharmacokinetics parameters for intravenous iron preparations are set out in Table 3.

Table 3: Pharmacokinetics parameters for some iron preparations

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Sodium ferric gluconate</th>
<th>Iron sucrose</th>
<th>Ferric carboxymaltose</th>
<th>Iron dextran USP/BP</th>
<th>Ferumoxytol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity with transferrin</td>
<td>High</td>
<td>Medium</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Dosage used for the pharmacokinetics characteristics (mg Fe)</td>
<td>125&lt;sup&gt;a&lt;/sup&gt;</td>
<td>100&lt;sup&gt;b&lt;/sup&gt;</td>
<td>100/1,000&lt;sup&gt;c&lt;/sup&gt;</td>
<td>500–2,000&lt;sup&gt;d&lt;/sup&gt;</td>
<td>316&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>terminal $k_{el}$ — first-order rate constant for elimination ($h^{-1}$)</td>
<td>0.488</td>
<td>0.145</td>
<td>0.094/0.074</td>
<td>0.024&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.048</td>
</tr>
<tr>
<td>terminal $t_{1/2}$ — half-life (h)</td>
<td>1.42</td>
<td>5.3</td>
<td>7.4/9.4</td>
<td>27–30&lt;sup&gt;f&lt;/sup&gt;</td>
<td>14.7</td>
</tr>
<tr>
<td>$C_{max}$ — peak concentration (mg Fe/L)</td>
<td>20.6</td>
<td>35.3</td>
<td>37/331</td>
<td>-</td>
<td>130</td>
</tr>
<tr>
<td>$AUC$ — area under the curve (mg Fe/L*h)</td>
<td>43.7</td>
<td>83.3</td>
<td>333/6,277</td>
<td>6,853&lt;sup&gt;e&lt;/sup&gt;</td>
<td>2,912</td>
</tr>
<tr>
<td>CL — clearance (L/h)</td>
<td>2.99</td>
<td>1.23</td>
<td>0.26/0.16</td>
<td>-</td>
<td>0.11</td>
</tr>
<tr>
<td>$V_c$ — Initial distribution volume (L)</td>
<td>2</td>
<td>3.2</td>
<td>2.7/2.1</td>
<td>3.0</td>
<td>2.3</td>
</tr>
</tbody>
</table>

<sup>a</sup> Study in iron deficient subjects<sup>131</sup>  
<sup>b</sup> Study in healthy volunteers<sup>132</sup>  
<sup>c</sup> Study in volunteers with mild iron deficiency anaemia<sup>133</sup>  
<sup>d</sup> Study in iron deficient patients<sup>134</sup>  
<sup>e</sup> Study in normal subjects and hemodialysis patients<sup>135</sup>  
<sup>f</sup> Calculated from a study conducted by Henderson et al. (1969) <sup>134</sup>  
<sup>g</sup> Calculated for a dose of 500mg iron by using $t_{1/2}$ (terminal $k_{el}$) and $V_d$  

**Side effects of IV iron**

Newer intravenous iron preparations rarely lead to infusion-related reactions. However, hypersensitivity-type and infusion reactions (approximate incidence 0.5%) are more common than for oral iron or placebo.<sup>120</sup> Severe hypersensitivity reactions and serious adverse events, such as anaphylaxis, are rare. Identification and management of these reactions have been extensively documented in the literature.<sup>120, 121, 136</sup>

Hypophosphataemia has been identified as one of the side effects of all types of IV iron preparations. This incidence appears to be linked to the molecules complexed to the iron rather than the iron itself.<sup>60</sup> Hypophosphataemia is more commonly observed with ferric carboxymaltose than with other formulations.<sup>137-139</sup> The rates of hypophosphataemia among various preparations are as follows: ferric carboxymaltose (58%), iron derisomaltose (4%) and iron sucrose (1%). However, the clinical importance of these rates has not been determined. Most cases involved are biochemically moderate (serum phosphate in the range 0.32–0.64 mmol/l) and asymptomatic, resolving without any intervention.<sup>140, 141</sup> Nonetheless, due to the rare association with hypophosphataemic osteomalacia, the Medicines and Healthcare Products Regulatory Agency (United Kingdom) issued a recommendation in 2020 suggesting monitoring serum phosphate levels in patients with risk factors for hypophosphataemia. This recommendation also extends to those who receive prolonged or multiple high-dose infusions of ferric carboxymaltose.<sup>142</sup>

Skin staining due to iron deposition, also referred to as cutaneous siderosis or haemosiderin staining, is a rare side effect associated with IV iron infusions.<sup>143</sup> Siderosis is characterised by iron accumulation in various tissues, leading to brownish-grey skin discoloration. Skin discoloration or extravasation at the infusion site occurs in approximately 1.6% of cases.<sup>144</sup> There have been a limited number of reported skin staining associated with IV iron, primarily involving ferric carboxymaltose,<sup>145 146</sup> iron sucrose<sup>144 148</sup> and iron polymaltose infusions.<sup>149 157</sup> This adverse effect can be concerning for patients from an aesthetic standpoint and may cause emotional distress.
IV iron administration demonstrates no increase in adverse events leading to treatment discontinuation and no increase in mortality. Additionally, there was no increased risk of severe adverse events related to cardiovascular, respiratory, neurological, thromboembolic, constitutional or gastrointestinal effects with IV iron administration.120

**Treatment duration and monitoring parameters**

The treatment goal of IV iron is to increase haemoglobin levels by at least 2 g/dl within four to eight weeks. It is recommended to conduct a follow-up assessment of haemoglobin and ferritin levels after at least four weeks following IV iron administration.64 This four- to eight-week window also allows sufficient time for erythropoiesis and iron utilisation.154 In cases of chronic ongoing blood loss, as seen in conditions such as hereditary abnormal uterine bleeding or haemorrhagic telangiectasia, more frequent follow-up appointments may be necessary to assess the treatment response and establish the appropriate dosing regimen. 64, 154 If haemoglobin and iron status fail to return to normal range, it is essential to carefully identify the underlying causes of this lack of improvement. 155

### 3.2.2 Blood transfusion for severe IDA

Red blood cell transfusion leads to an immediate and transient increase in haemoglobin levels, delivering around 200–250 mg of iron per blood unit.78 However, red blood cell transfusion is not the recommended approach for treating IDA, except when urgent oxygen delivery elevation is needed, such as when patients have angina pectoris or cardiac failure, or when IDA is complicated by severe, ongoing acute bleeding.118

Patients with severe IDA, which is characterised by Hb levels below 7 g/dl, with symptoms of insufficient oxygen delivery (e.g., syncope, chest pain) are likely to gain benefit from transfusion. However, most patients with severe anaemia generally experience fatigue and do not require transfusion. If the decision is made to transfuse a patient for IDA, a single unit of red blood cells is often sufficient. Further increases in Hb can be facilitated through oral or intravenous iron.156

The Choosing Wisely campaigns, operating across different jurisdictions and medical specialties, have underscored the importance of restricting red blood cell transfusions. They encourage the selection of alternative therapeutic approaches when they are appropriate and accessible. They encourage the selection of alternative therapeutic approaches when they are appropriate and accessible.156-159 The risks linked to transfusion include transmitting infectious diseases, transfusion-associated lung injury, haemolytic transfusion reactions, cardiac overload due to transfusion, and alloimmunisation.160 Red blood cell transfusion as a treatment option for patients with IDA is not only unfavourable from a diagnostic perspective but also in terms of cost-effectiveness.160 Transfusions’ financial and ethical implications can vary based on how they are calculated.161 Healthcare professionals are advised to refrain from transfusing red blood cells for individuals with iron deficiency, regardless of their haemoglobin levels, unless there is a lack of haemodynamic stability.156, 162
3.3 Non-pharmacological interventions

3.3.1 Dietary modification

Pharmacists can empower individuals to make informed dietary choices through their role in nutritional education in collaboration with dietitians. The optimal approach to improving iron levels involves a combination of strategies such as introducing iron-rich foods into the diet, food fortification, using “enhancers” to improve micronutrient absorption, avoiding substances that hinder micronutrient absorption (“inhibitors”), and harnessing beneficial food processing techniques.

3.3.1.1 Iron-rich foods

Incorporating various iron-rich foods into the diet is essential, and it is equally important to consider how the body can effectively absorb iron from dietary sources. It depends on the type of iron consumed from different food sources with different absorption levels in the body.

Iron-rich foods encompass animal and plant sources. Haem iron is the most common in daily diets and is present solely in animal-based products. It demonstrates a high bioavailability, approximately between 25% and 30%. On the other hand, non-haem iron, found in plant- and animal-based products, shows a bioavailability range of around 1% to 10%. Incorporating haem iron derived from animal-based sources (particularly beef, lamb, pork and chicken) into non-haem iron meals will further enhance the overall bioavailability and absorption of iron from a meal. Some foods containing haem iron and non-haem iron can be seen in Figure 8 and Figure 9, respectively.

Improving dietary diversity is important; however, the expense and accessibility of animal products and fruits and vegetables frequently constrain patients in their efforts to get more nutritious food. It is essential for pharmacists to consider their patients’ socio-economic conditions when advising an increase in the intake of iron-rich foods.
3.3.1.2 Food fortification

Food fortification refers to adding micronutrients to food and beverages, thereby enriching their nutritional content, using, for example, meal ingredients or condiments. This can include using isolated iron compounds, such as iron salts or chelates, or ingredients naturally rich in iron, such as meat and its derivatives. The selection of these compounds is determined by the intended characteristics of the final product, such as taste and colour, and may be influenced by costs. Iron is most commonly fortified in wheat and maize flour, infant formula and cereals.

According to the WHO, several iron compounds are used for fortification in food. They are divided into three types based on their solubility properties, namely, freely soluble (usually the preferred option), poorly water-soluble but soluble in dilute acids, and water-insoluble and poorly soluble in dilute acids. These three types of iron compounds are as follows:

- **Iron compounds that are water-soluble** — Ferrous sulfate, ferrous gluconate, ferrous lactate and ferric ammonium citrate are used to fortify products such as pasta, edible salt, flour and infant foods. They can change the colour and taste of food products.

- **Iron compounds that are poorly water-soluble but soluble in dilute acids** — Ferrous fumarate is commonly used to fortify infant cereals, and ferric saccharate is utilised in chocolate drink powders. They induce fewer alterations in the taste and colour of the final product.

- **Iron compounds that are water-insoluble and poorly soluble in dilute acids** — Ferric phosphate compounds, such as ferric orthophosphate and ferric pyrophosphate, are used to fortify rice, certain infant cereals and foods containing chocolate. They have lower absorbability, but they do not affect the organoleptic characteristics of the food product, making them a viable choice. They are also more cost-effective than the other types. However, they are generally considered a last-resort option, particularly when the target population’s diet contains inhibiting factors for iron absorption.

Encapsulated forms of several iron compounds are readily available in the market. These include ferrous sulfate and ferrous fumarate, coated with hydrogenated oil, such as soybean, cottonseed or ethyl cellulose. The encapsulated coatings in iron compounds play a role in preventing oxidative damage, thereby mitigating sensory changes to fortified food products.
3.3.1.3 Enhancing iron absorption

Adding "enhancers" such as citric acid, malic acid or vitamin C may enhance iron absorption from plant-based foods. For example, consuming foods rich in vitamin C, such as citrus fruits, strawberries and bell peppers, can enhance absorption of non-haem iron.

3.3.1.4 Avoiding iron inhibitors

Reducing the intake of certain foods and beverages, such as tea and coffee, which contain compounds that can hinder iron absorption, can be advantageous. Moreover, the bioavailability of iron compounds is not solely determined by their solubility properties but is also influenced by dietary composition. This includes the proportion of iron-inhibiting factors in the diet, notably iron-binding phytates found in cereals and other staple foods like sorghum and pulses, as well as polyphenolic compounds in fruits and vegetables.

3.3.1.5 Harnessing beneficial food processing techniques

Food processing methods, such as soaking, fermentation, germination and thermal or mechanical processes, can also improve iron bioavailability and absorption from non-animal sources. For example, soaking and sprouting cereal and pulse grains results in a decrease in phytate content and an increase in iron absorption.

3.3.2 Lifestyle modification

Lifestyle modifications play a role in the comprehensive management and treatment of IDA. Patients are encouraged to adopt various general practices to improve their condition. Lifestyle recommendations that pharmacists can advise include:

- It is important patients follow recommendations from healthcare professionals regarding supplementation and dietary changes to manage their iron levels effectively.
- Patients can be encouraged to have a diet rich in iron-containing foods, such as lean meats, beans and dark leafy greens, and pair them with vitamin C-rich foods, such as citrus fruits, to enhance absorption. Limiting the consumption of substances inhibiting iron absorption, such as excessive tea or coffee, can also be beneficial.
- Staying well-hydrated aids in the optimal absorption of dietary iron.
- Regular health check-ups are important for monitoring iron status and overall well-being.
- Patients who regularly donate blood should remain vigilant by monitoring their iron levels and adhering to responsible blood donation guidelines to ensure it does not compromise their health.
- Treating the underlying cause is crucial in managing IDA. There could be a possibility where healthcare professionals recommend additional tests or treatment to address the root issue.

3.4 Supporting pharmacists’ roles in IDA treatment and management

3.4.1 Patient counselling guide steps

Patient adherence and treatment compliance can enhance haematological indices in patients with IDA, which can be done through patient counselling over time. Creating a comfortable and conducive environment for patient counselling is important as it fosters open engagement and understanding.

Figure 10 illustrates patient counselling guide steps to optimise patient outcomes and improve patient adherence and treatment compliance.
3.4.1.1 Establishing open-ended communication

Communication is a tool that is needed to establish a connection with the patient. An open-ended communication can be established through the following:

- Creating a safe communication environment by initiating an introduction as the attending healthcare provider. To ensure effective communication, it is important to confirm the patient’s preferred language and communicate using it. In cases of a language barrier, use an interpreter to facilitate the discussion.
- Obtaining patient’s consent to continue the conversation and confirm if the patient has ever been diagnosed with IDA.

3.4.1.2 Assessing patient’s knowledge about IDA

Patients’ health literacy is important as it links to medication adherence, and pharmacists are recommended to assess patients’ knowledge about IDA. Patients should be asked open-ended questions to evaluate their knowledge.

1. For patients not diagnosed with IDA, assess their knowledge by:
   a. Gathering their medical and medication histories, including their dietary habits and other risk factors (see Section 3.1.2: Medical and medication histories for details).
   b. Identifying their signs and symptoms, such as fatigue, pallor and shortness of breath (see Section 3.1.1: Signs and symptoms for details).
   c. Confirming IDA diagnosis through test results in collaboration with other healthcare professionals (see Section 3.1.3: Examination and investigation for details).
   d. Continue to the steps under point 2 (patient diagnosed with IDA) below.

2. For patients diagnosed with IDA, to avoid misconception and promote adherence to medication, their knowledge should be assessed by:
   a. Understanding their attitude towards and perception of IDA. This is through acknowledging and confirming patients’ symptoms and asking about their treatment goals so the approach will be patient-centred by building on their goals.
   b. Gathering their complete medication history, which relates to any prior health conditions they may have experienced.
   c. Providing them with non-pharmacological advice, which includes dietary change advice.
3.4.1.3 Educating patients

Some points that could be considered in educating patients are as follows:

- **Iron repletion therapy** — Dosage, Results, Underlying issues, and General information (DRUG) method can be used to educate patients on iron repletion therapy and cover important aspects of medication counselling.178
  
  a. **D (Dosage)** — Ensure that patients know the proper dosage and administration instructions by directing them to the prescription information of specific iron therapy.
  
  b. **R (Results)** — Discuss that the treatment duration may extend up to six months, aligning with the time needed to improve clinical blood parameters during regular treatment. Additionally, explore the potential consequences of not adhering to the prescribed regimen.
  
  c. **U (Underlying Issues)** — Discuss all possible side effects and difficulties patients may experience with iron therapy. Also, discuss possible drug interactions that may affect the effectiveness of these treatments and potential gastrointestinal issues that patients may encounter, particularly with oral iron therapy. Patients can also be advised on how to manage or minimise side effects, such as by (i) drinking sufficient fluid if medically appropriate to minimise constipation; (ii) switching to every other day dosing or taking with food if intolerable gastrointestinal side effects; (iii) switching to formulation which has evidence for lower incidence of constipation due to incorporation of ingredient such as sorbitol181; and (iv) drinking water or chewing gum to possibly help reduce the metallic taste.
  
  d. **G (General Information)** — Broaden the discussion to encompass all aspects of blood health. Elaborate on how various micronutrients, including folic acid (particularly vital for expectant mothers), vitamin C, vitamins B12 and B6, copper and manganese, play essential roles in maintaining overall blood health. Additionally, provide guidance on the correct usage and storage of medicines and ensure that patients are informed about whom to contact for any inquiries or concerns.

- **Dietary changes** — Dietary changes and food diversification can boost iron intake. Pharmacists play an important role in promoting healthy lifestyles and can educate patients on various food sources (see Section 3.3: Non-pharmacological ).43, 178, 182

- **Follow up** — Appropriate therapy follow-up should also be communicated with patients. A 30-day follow-up is recommended to determine parameters such as haemoglobin, blood cell indices and iron status to assess treatment response. If therapy is continued, subsequent follow-ups at six-month intervals should be conducted to monitor response status.

- **Substandard and falsified medicines** — Substandard and falsified medicines cause harm to patients and affect all regions of the world.183 Educating patients on the importance of getting medicines from registered pharmacy outlets and not from unregulated platforms online or illegal street markets is important.

3.4.1.4 Obtaining feedback to validate patients’ new knowledge

Pharmacists can do the following to obtain feedback from patients:

- **Assess patient’s understanding** — Devote time to verify patients’ understanding of IDA and lifestyle changes needed to manage their condition.178

- **Encourage descriptive insight** — Ask patients to describe how they will use the medicines that have been prescribed.178 Leverage this opportunity to address any concerns or questions they might have.178

- **Observe medicines use capability** Identify any potential barriers to adherence by observing the patient’s attitude and providing more necessary information to address any concerns.178

3.4.2 Flowchart of IDA treatment and management in primary and secondary care settings

Early intervention of IDA enhances physical and mental well-being, reduces fatigue and cognitive impairment, alleviates other symptoms and complications and improves quality of life.153 Collaborative approaches among health professionals are essential in effectively managing IDA. Figure 11 illustrates IDA treatment and management for adults in primary and secondary care settings.
Iron deficiency anaemia: Managing symptoms and supporting self-care

Figure 11: Treatment and management of IDA in adults

*Severe anaemia generally refers to a haemoglobin level of <7 g/dL or anaemia with symptoms of hemodynamic compromise or cardiac ischemia.

Some additional management considerations include:

- Determine the cause of IDA such as lack of dietary iron, conditions that interfere with absorption, heavy menstrual bleeding, and source of gastrointestinal blood loss.
- IV iron therapy is administered when a rapid increase in serum ferritin level is required or other chronic diseases, such as inflammatory bowel disease, gastrectomy bariatric surgery and dialysis-dependent kidney disease are present. Refer to Section 4 for IDA management in patients with chronic diseases.
- IV iron can be given in the second and third trimesters of pregnancy but not the first trimester (due to lack of safety data in the first trimester). Refer to Section 4 for IDA management in pregnant women.
- Oral iron can be dosed daily or every other day (preferred) for up to 6 months depending on iron deficit.
- Oral iron can be taken after food to reduce gastrointestinal side effects.
- Oral iron should be taken two hours apart from other medications.
- Once Hb has normalised, treatment should be continued for about 3 months.
- Refer to Section 4 for IDA management in special populations.
4 IDA management in special populations

Despite the efforts in diagnosing the condition and the accessibility of therapeutic iron preparations, IDA still affects a significant number of people and special populations. The approach to effective management of IDA requires early identification, accurate diagnoses, individual-based tailored interventions and patient education. Although IDA treatment involves a combination of dietary changes and oral and parental iron therapy, the differences and uniqueness of each population should be considered when addressing this condition. The underlying cause of IDA should be identified for patients who require immediate management to receive optimal care and ultimately experience improved health. This section aims to provide pharmacists with the necessary knowledge on managing IDA in some special populations.

4.1 Paediatrics

Anaemia is defined in the paediatric population as:

- **Infants and toddlers (0.5–5 years old)** — Haemoglobin concentration <11 g/dl
- **Children (5–12 years old)** — Haemoglobin concentration <11.5 g/dl
- **Adolescent females (>12 years old)** — Haemoglobin concentration <12 g/dl
- **Adolescent males (12 years old)**: Haemoglobin concentration <13 g/dl

Possible causes of anaemia in paediatrics are as follows:

- **Infants** — Infants with specific risk factors, such as infants of iron-deficient mothers (there is an increased risk of small for gestational age/growth restriction), those with low birth weight or prematurity (as these can limit their iron stores at birth), multiple pregnancies, early introduction of cow milk (as cow milk can hinder iron absorption), exclusive breastfeeding beyond six months of age (as prolonged exclusive breastfeeding without iron fortification can lead to iron deficiency) and lack of infant iron supply.
- **Children under five years old** — Children aged under five years are vulnerable to IDA due to their rapid growth and development, increased iron requirements, and often limited dietary diversity.
- **Adolescents** — Both male and female adolescents face a higher risk of IDA. Factors contributing to this risk include inadequate dietary iron intake, susceptibility to parasitic infections like malaria and worms, heavy menstrual bleeding, gastrointestinal disorders, other chronic blood loss, and extreme athletics.

Apart from possible signs and symptoms of ID in Section 3.1.1: Signs and symptoms, some other signs and symptoms that can be looked out are developmental delays, frequent tiredness, less activeness as compared with completely healthy children, motor and cognitive retardation, and mood disorders. The preventive dose for the paediatric population is set out in Section 5.3.1. Iron supplements. Table 4 provides some iron formulations available for paediatric prescription.

Some key points to consider in managing IDA in this special population include:

- Inform parents that iron supplements may cause black stool and constipation in children.
- To prevent tooth staining, consider having the child use a straw when taking oral iron supplements and suggest brushing their teeth after consumption.
- Continue iron supplementation for a minimum of three months after anaemia correction to replenish iron stores. Monitor haemoglobin (Hb) and ferritin levels at this point.
- For children with severe anaemia, schedule an early follow-up within a week to ensure treatment compliance and a proper response (e.g., reticulocytosis and Hb increase).
- Evaluate potential issues related to treatment compliance, as non-compliance is the primary reason for treatment failure.
- Encourage parents to increase their child’s intake of iron-rich foods and reduce cow milk consumption. Avoid giving cow milk to children under 12 months and limit it to less than 500 ml per day for those older than 12 months.
- If babies are premature, consider delaying the clamping of the cord.
- It is recommended to do exclusive breastfeeding in the first six months, and solid foods that are given after six months should be rich in iron, zinc, phosphorus, magnesium, calcium and vitamin B6.
- Refer patients to a dietitian for dietary guidance.

Table 4: Available iron formulations for paediatric prescription

<table>
<thead>
<tr>
<th>Iron formulation*</th>
<th>Recommended dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrous sulfate/ferrous gluconate</td>
<td>2–6mg/kg/day</td>
<td>This is a standard treatment with good intestinal absorption and low cost. Side effect happens in 15–32% of cases and include an unpleasant taste. A low dosage, i.e., 2mg/kg/day, has been proposed as a still efficacious and better-tolerated schedule.</td>
</tr>
<tr>
<td>Ferrous fumarate</td>
<td>12.5mg/day (6–24 months of age); 20–30mg/day (2–5 years of age); 30–60mg/day (6–11 years of age)</td>
<td>Drop and syrup formulations are available.</td>
</tr>
<tr>
<td>Ferrous glycinate</td>
<td>0.45mg/kg/day</td>
<td>Good intestinal absorption, limited side effects, and drop formulation available.</td>
</tr>
<tr>
<td>Ferric pyrophosphate transported within a phospholipid membrane (liposomal iron)</td>
<td>1.4mg/kg/day</td>
<td>Excellent palatability, limited side effects, drop formulation available. Possible less prompt response to therapy.</td>
</tr>
<tr>
<td>IV iron gluconate</td>
<td>Total dose to be calculated based on initial Hb and weight</td>
<td>Effectiveness is independent of gastro-enteric absorption and very low gastro-enteric side effects. Hospitalisation is required, along with multiple infusions.</td>
</tr>
<tr>
<td>IV carboxymaltose iron</td>
<td>The dose to be calculated based on initial Hb and weight</td>
<td>Effectiveness is independent of gastro-enteric absorption, single administration, and indication for adolescents ≥14 years. Hospitalisation is required.</td>
</tr>
</tbody>
</table>

*There can be variation in the licensing of different medicines containing the same drug. Preparations can be in the form of oral suspension, oral solution, drop, drinkable vials, tablets, capsules or spansules.

4.2 Non-pregnant women of reproductive age

Women of reproductive age, especially those with heavy menstrual bleeding, are at increased risk of IDA, and they should be promptly treated for cause. Some may not respond well to oral iron in the short term. In such cases, IV iron therapy is recommended, especially for women planning pregnancy, as it is more likely to achieve iron sufficiency before conception.

4.2.1 Heavy menstrual bleeding

Heavy menstrual bleeding (HMB) may affect up to 50% of women of reproductive age. Normally, the blood loss during a menstrual cycle is between the range of 25–50 ml; however, patients with HMB experience a blood loss greater than 80 ml per cycle and excessive menstrual blood loss leading to interference with the physical, emotional, social or material well-being. Symptoms such as abnormal frequency, regularity and the unpredictable onset of
menstruation might be due to abnormal uterine bleeding. Pharmacists can support identifying possible patients with HMB and refer them to a gynaecologist to confirm the diagnosis and treatment.

The goals of HMB management include reducing or stopping blood loss and supplementing for iron loss. The first-line intervention for HMB patients diagnosed with mild to moderate IDA is the use of oral iron therapy. Specific instructions should be given regarding dosing intervals and interactions with substances that can hinder absorption. Dietary changes can be advised, but this is insufficient as the only way to replenish iron stores. Pharmacists can provide counselling after the treatment is confirmed (see Section 3.4.1: Patient counselling guide steps).

In cases of intolerance due to frequent administration of oral iron therapy, the drug should be administered on alternate days to optimise treatment outcomes. If there is no improvement in the level of Hb within a month of therapy, the treatment approach should be reassessed. In severe cases of IDA and intolerance to oral therapy or urgency, iron stores can be rapidly restored by administering IV iron therapy.

In addition, hormonal and non-hormonal therapy can be used in treating blood loss in HMB patients. The most preferred hormonal treatment is the use of 52 mg levonorgestrel-releasing intrauterine system, and other treatments include depot medroxyprogesterone acetate, combined oral contraceptive pills, gonadotropin-releasing hormone analogues and selective progesterone receptor modulators. The administration of NSAID and antifibrinolytic agents such as tranexamic acid are non-hormonal treatments used in managing HMB in individuals intending to get pregnant or who cannot use the hormonal treatment. Gonadotropin-releasing hormone agonist can be used as a short-term solution to boost iron stores and is also appropriate for women who undergo surgery.

Women with HMB and IDA require a combined approach of medical and surgical measures in cases where medical treatment is not effective alone. Preoperative amenorrhoea is also necessary before carrying out any surgical measures. For women planning to get pregnant, Hb level and iron status should be assessed, and if deficient, appropriate treatment should be advised before they attempt conception.

Figure 12 describes the flowchart of IDA management for HMB patients.
4.2.2 Women with birth control

Another population that is part of women of reproductive age that will be discussed is those who are with birth control. There are two types of contraceptives — hormonal and non-hormonal. Hormonal contraceptives include hormonal intrauterine devices (IUDs), oral contraceptives and vaginal rings, while non-hormonal contraceptives include barrier methods such as condoms, copper IUDs, the withdrawal method, and the fertility awareness method used to monitor a woman’s fertility cycle. The use of oral contraceptives is beneficial for those with haematological disorders and diagnosed with IDA because it alters the hormones, reduces blood loss and is beneficial for family planning. Other types of contraceptives, including hormonal IUDs, patches, rings and injections, can be used for similar purposes and benefits. In contrast, copper IUDs are not advised for use because they increase the loss of blood in haemorrhagic patients.

The combination of contraceptives and iron supplements has been found to be beneficial in the prevention of IDA. Nevertheless, iron-containing oral contraceptives can be used instead of non-iron oral contraceptives, although the benefits and differences have not yet been identified from the study done so far.

4.3 Pregnant women and breastfeeding mothers

In pregnancy, the demand for iron by the fetus becomes critical after 28–32 weeks for fetal brain development. The period from conception to the infant’s second year is crucial because of brain development. Without effective management of anaemia in pregnancy, some adverse fetal outcomes could occur, including preterm birth, low birth weight, impaired neurodevelopmental outcome and perinatal death. Breastfeeding mothers need to provide iron through breast milk for their infants. If their iron stores are depleted or their dietary intake is inadequate, they can become vulnerable to IDA.

Anaemia is defined in pregnant women and breastfeeding mothers as:

- **First and third trimester of pregnancy** — Haemoglobin concentration of less than 11 g/dl (Hct 33%).
- **Second trimester of pregnancy** — Haemoglobin concentration of less than 10.5 g/dl (Hct 32%).
- **Breastfeeding mothers** — Haemoglobin concentration of less than 10 g/dl.

Clinical symptoms cannot be relied on alone to diagnose IDA in pregnancy; however, all signs and symptoms should be watched for (see signs and symptoms section). Low haemoglobin, mean cell volume, mean cell haemoglobin, mean cell haemoglobin concentration and serum ferritin (30 microgram/l) are indicative of ID in pregnancy. The values obtained must be interpreted cautiously because of the physiological changes in pregnancy.

The management of IDA in this special population includes preventive oral iron and folic acid supplements (see 5.3.1: Iron supplements for the preventive dose), accompanied by diet, oral or parenteral iron therapy and blood transfusions, if necessary.

4.3.1 Oral iron supplements

Table 5 outlines different criteria for administering oral iron therapy and conducting serum ferritin tests in both anaemic and non-anaemic pregnant women.

Initially, the recommended daily dose of elemental iron for treating IDA was 100–200 mg. However, recent studies indicate that lower doses or intermittent supplementation may be beneficial to minimise side effects (such as gastric irritation, nausea, constipation, disturbed bowel function). Collectively, evidence and recommendations from guideline and expert consensus suggest lower dose which is 30–60mg elemental iron to be effective while minimising side effects. Hb should be monitored at two to three weeks to ensure an adequate response to oral iron treatment. Daily folic acid (400 microgram) is also necessary before the 12 weeks of gestation to reduce the risk of neural tube defects. The use of enteric-coated or timed-release formulations could be avoided as it demonstrated low levels of bioavailability.
Table 5: Criteria for conducting serum ferritin tests and administering oral iron therapy

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaemic women with known haemoglobinopathy or who require parenteral iron repletion therapy.</td>
<td>A serum ferritin test should be conducted prior to administering oral iron therapy.</td>
</tr>
<tr>
<td>Non-anaemic women at high risk of low iron, including</td>
<td></td>
</tr>
<tr>
<td>• Previous anaemia</td>
<td></td>
</tr>
<tr>
<td>• Women who have had many pregnancies</td>
<td></td>
</tr>
<tr>
<td>• Twin or higher-order multiple pregnancy</td>
<td></td>
</tr>
<tr>
<td>• Interpregnancy interval &lt;1 year</td>
<td></td>
</tr>
<tr>
<td>• Women who have poor dietary habits</td>
<td></td>
</tr>
<tr>
<td>• Those following a vegetarian/vegan diet</td>
<td></td>
</tr>
<tr>
<td>• Pregnant teenagers</td>
<td></td>
</tr>
<tr>
<td>• Recent history of clinically significant bleeding</td>
<td></td>
</tr>
<tr>
<td>Non-anaemic women with:</td>
<td></td>
</tr>
<tr>
<td>• High risk of bleeding during pregnancy or at birth</td>
<td>Serum ferritin may be necessary</td>
</tr>
<tr>
<td>• Women declining blood products, such as Jehovah’s Witnesses</td>
<td></td>
</tr>
<tr>
<td>• Women for whom providing compatible blood is challenging</td>
<td></td>
</tr>
</tbody>
</table>

Women of reproductive age often experience multiple-micronutrient deficiencies, increasing their risk of ID and IDA. Iron with multivitamins and multimineral supplementation proves effective in preventing and treating mild to moderate IDA. A study demonstrates that a 90-day regimen of this supplementation significantly improves haemoglobin levels, ferritin, quality of life and IDA symptoms, with early Hb level increase observed by day 14 for moderate IDA subjects. The treatment is well-tolerated, with minimal adverse events. These findings support the use of iron with multivitamin and multimineral supplementation for treating IDA across different patient populations, contributing to the reduction of the global health burden associated with IDA.

Apart from the counselling points for the general population (see Section 3.4.1: Patient counselling guide steps), information that pharmacists should give pregnant women and breastfeeding mothers includes:

- It is advised to take the supplement on an empty stomach first thing in the morning due to the low levels of hepcidin in the morning.
- If point-of-care testing is available, it is advised to check for haemoglobin levels biweekly to ensure adequate response to the medication.
- Other medicines, such as antacids and vitamins, should not be taken with iron supplements (usually, it is recommended to take two hours apart from milk and calcium supplements).
- It is important to discuss common adverse effects such as constipation, metallic taste, enlarged uterus, and nausea, and recommend non-pharmacological treatment and laxatives, such as sorbitol, that are safe in pregnancy if necessary.

4.3.2 Parenteral iron therapy

The decision to use parenteral iron therapy instead of oral iron should be based on the patient’s needs, and the goal of the therapy should be to increase the haemoglobin level to at least 11 g/dl. Table 6 shows indications and contraindications in the choice of IV iron for managing IDA in pregnant women and breastfeeding mothers.
Table 6: Indications and contraindications in the choice of IV iron in pregnant women and breastfeeding mothers

<table>
<thead>
<tr>
<th>Indications</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Failure to respond to oral iron therapy</td>
<td>Lack of facilities for resuscitation</td>
</tr>
<tr>
<td>Non-compliance or intolerance to oral iron</td>
<td>Known history of anaphylaxis or reactions to IV iron therapy</td>
</tr>
<tr>
<td>Late second or third trimester with moderate to severe IDA</td>
<td>Gestation period less than 12 weeks</td>
</tr>
<tr>
<td>Malabsorption (e.g., bowel resection/coeliac disease)</td>
<td>Known state of iron overload</td>
</tr>
<tr>
<td>Bleeding diathesis when haemorrhage is likely to continue</td>
<td>First trimester of pregnancy*</td>
</tr>
<tr>
<td>In combination with recombinant erythropoietin patients with pregnancy</td>
<td>Active or chronic bacteraemia</td>
</tr>
<tr>
<td>and chronic disease</td>
<td>Decompensated liver disease</td>
</tr>
<tr>
<td>Moderate to severe post-partum anaemia when compliance with oral iron</td>
<td></td>
</tr>
<tr>
<td>therapy and follow-up in the health care facility is doubtful</td>
<td></td>
</tr>
</tbody>
</table>

*Although IV iron is not recommended in the first trimester, it can be administered when the benefits outweigh the risk, especially in cases where the potential risk will affect the neurodevelopment of the fetus. This should be done with proper counselling and monitoring.

Figure 13 illustrates the treatment of ID/IDA in pregnant women.

*First trimester: mild IDA (10.0–10.9 g/dl), moderate IDA (7–9.9 g/dl),
Second and third trimester: mild IDA (9.5–10.4 g/dl), moderate IDA (6.5–9.4 g/dl)

Figure 13: Flowchart for the ID/IDA treatment in pregnant women
4.4 The elderly and patients with chronic diseases

4.4.1 Elderly patients

IDA is the second most common cause of anaemia in elderly patients, accounting for 15–30% of anaemic cases in those over 85 years of age. The causes of anaemia in this population are multiple and complex, including poor diet, reduced iron absorption, occult blood loss, medication (e.g., aspirin) and chronic disease (e.g., chronic kidney disease, chronic heart failure). In addition to the other symptoms of IDA from Section 3.1.1: Signs and symptoms, patients could present with weakness of the body and derailed cognitive function.

The goal of IDA management in this population is to alleviate IDA, replenish iron stores, and treat any underlying disease. As in other special groups, the first-line treatment for IDA in this population is the administration of oral iron therapy, dietary changes and parenteral iron therapy, which can also be administered in cases of intolerance to oral therapy. The recommended daily dose of elemental iron is in the range of 60–200 mg, and intravenous iron has also shown high efficacy in patients who cannot tolerate oral therapy, but it has been reported to have side effects such as anaphylaxis in 0.5–1% of treated patients.

It is important to note that a personalised approach that considers comorbidities, drugs and the potential effects of ageing should be considered when managing elderly patients. Pharmacists should be able to provide information in easy-to-understand terms and assist elderly patients to improve their iron status and general health outcomes.

A wide range of co-morbidities in elderly patients could contribute to developing IDA; hence, early and proper diagnosis is beneficial for optimum care.

4.4.2 Patients with chronic diseases

Patients with IDA could present with chronic diseases which are associated with systemic inflammation, such as chronic kidney disease, cirrhosis, heart failure, inflammatory bowel syndrome and cancer. This section will describe brief management of patients with chronic heart failure, chronic kidney disease and inflammatory bowel syndrome.

4.4.2.1 Chronic Heart failure

Patients with chronic heart failure (CHF) have preserved ejection fraction or reduced ejection fraction. The cause of IDA is multifactorial, including malabsorption, malnutrition, gastrointestinal blood loss and chronic inflammation, which could increase the level of hepcidin, thereby decreasing the uptake and absorption of iron.

IDA is defined in CHF patients as serum ferritin <100 microgram/l and/or a TSAT of <20%. In cases where IDA is due to CHF, it is recommended to check causes from the gastrointestinal tract through an endoscopic evaluation. A collaborative approach with a cardiologist is crucial for diagnosis confirmation and treatment.

Randomised studies to assess the effectiveness of oral or IV iron therapy in CHF patients are limited; however, studies have been carried out in patients with reduced ejection fraction, and oral iron therapy has demonstrated no prognostic benefit due to low absorption and side effects such as oedema. IV iron is recommended to improve the patient’s quality of life and prognosis.

4.4.2.2 Chronic kidney disease

Anaemia in patients with chronic kidney disease (CKD) is common and associated with poor quality of life and increased mortality. Factors contributing to iron deficiency are chronic inflammation and poor hepcidin clearance seen in CKD.

Iron supplements with erythropoiesis-stimulating agents are the management choices in this population. Iron supplementation can be administered orally, intravenously or intradialytically (during haemodialysis sessions). Iron therapy should be chosen based on the severity of iron deficiency, availability of venous access, response and side effects from prior iron therapy, patient compliance and cost.
Table 7 shows recommendations from the Kidney Disease Improving Global Outcomes guidelines on appropriate treatment regimens for patients with CKD. A multidisciplinary approach is crucial in CKD patient management.227, 231

Table 7: Iron therapy management in patients with chronic kidney disease (CKD)232

<table>
<thead>
<tr>
<th>Patient treatment</th>
<th>Population</th>
<th>Threshold for iron therapy*</th>
<th>Recommended therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient is not currently on Erythropoiesis-Stimulating Agents (ESA) or iron therapy</td>
<td>Paediatric CKD patients</td>
<td>TSAT ≤20% and ferritin &lt;100 microgram/l</td>
<td>Trial of oral iron (or trial of IV iron in CKD-Haemodyalisis (CKD HD))</td>
</tr>
<tr>
<td>Adult CKD patients</td>
<td></td>
<td>Increase in Hb concentration without ESA initiation is desired AND TSAT ≤30% and ferritin ≤500 microgram/l</td>
<td>Trial of IV iron (or trial of oral iron for 1 to 3 months in CKD-Non-haemodyalisis (CKD ND))</td>
</tr>
<tr>
<td>Patient is taking ESA therapy and not on iron therapy</td>
<td>Paediatric CKD patients</td>
<td>TSAT ≤20% and ferritin &lt;100 microgram/l</td>
<td>Trial of oral iron (or trial of IV iron in CKD HD)</td>
</tr>
<tr>
<td>Adult CKD patients</td>
<td></td>
<td>Increase in Hb concentration, or decrease in ESA dose is desired, and TSAT ≤30% and ferritin ≤500 microgram/l</td>
<td>Trial of IV iron (or trial of oral iron for 1 to 3 months in CKD ND)</td>
</tr>
</tbody>
</table>

*Evaluate iron status (TSAT and ferritin) at least every three months during ESA therapy, including the decision to start or continue iron therapy. Test iron status (TSAT and ferritin) more frequently when initiating or increasing ESA dose, when there is blood loss, when monitoring response after a course of IV iron, and in other circumstances where iron stores may be depleted.

4.4.2.3 Inflammatory bowel disease

Inflammatory bowel disease (IBD) is another chronic disease of inflammation in the gastrointestinal tract. While oral iron therapy is indicated for mild anaemia and inactive disease, it is recommended that it should be less than 100 mg of elemental iron.60 Oral iron in IBD patients can worsen symptoms and disrupt the intestinal microbiome if it is not tolerated.233, 234 The absorption of oral iron may be impaired by the systemic inflammatory process, as well as by small bowel involvement and/or previous surgery, which favours IV iron as the first-line therapy.235

Figure 14 illustrates a summary of IDA management and treatment in chronic disease patients.
4.5 Patients with chronic blood loss

4.5.1 Gastrointestinal bleeding

Gastrointestinal bleeding is the second most common cause of blood loss in men and postmenopausal women. IDA is estimated to be present in 61% of those with gastrointestinal bleeding, and studies have shown that it is underdiagnosed, under-recognised and undertreated, especially in hospitalised patients. The blood loss could go unnoticed because it occurs in small amounts with bowel movement. However, blood in the stool can be detected through a haemoccult slide test (a test of faecal occult blood) during further investigation. Other investigation includes upper GI endoscopy and colonoscopy.

IDA treatment for this population aims to restore the haemoglobin level, serum ferritin levels and transferrin saturation to normal. Patients are first started on oral therapy; in other cases, parenteral iron can be administered. The indications for parenteral iron therapy are patients who are intolerant to oral therapy or who have possible intestinal malabsorption, and suspected non-adherence to oral therapy is observed. Blood transfusion should be considered to improve treatment outcomes in patients with persistent bleeding, heart disease, haemoglobin level less than 7 g/dL, comorbidities or postoperative care and symptomatic anaemia. If the cause of gastrointestinal bleeding is ulceration, the use of anti-inflammatory medicines such as NSAIDs and blood-thinners should be avoided.

For individuals who have had bariatric surgery or other procedures that affect the duodenum, taking oral iron therapy may not be effective. Similarly, where there are problems with blood vessels in the digestive tract (gastrointestinal tract angiodysplasia), oral iron therapy may not be able to replace the blood loss quickly. In these conditions, it is advised to use IV iron rather than oral iron.

4.5.2 Bleeding disorders

Bleeding disorders occur due to the absence or deficiency of some clotting proteins. The most common types of bleeding disorders are haemophilia A, haemophilia B and von Willebrand disease.

Pharmacists need to encourage patients with bleeding disorders to optimise iron intake and absorption since they are at a higher risk of IDA. This can be done by recommending patients take 100–200 mg of elemental iron daily to increase gut absorption to at least 5 mg per day. Food rich in iron should be consumed regularly. In addition, medicines that interfere with iron absorption, such as proton pump inhibitors, should be avoided. The underlying bleeding disorder should be managed to prevent further blood loss.
Figure 15 illustrates a summary of IDA management and treatment in patients with chronic blood loss.

Figure 15: Summary of IDA management and treatment in patients with chronic blood loss

4.6 Individuals on strict diets

Patients on strict diets are commonly vegetarians who do not take protein from animals but consume dairy foods and eggs from animals and vegans who do not consume any animal protein-based products.244 Foods from plant sources only contain non-haem iron, obtained from sources such as legumes, peas, nuts and seeds, and wholegrain cereals (see Figure 9: Food containing non-haem iron in Section 3.3.1.1: Iron-rich foods). However, studies have shown that there might be no difference in the iron level between these populations and others; it is advised that in addition to iron supplementation, biofortified food can be consumed to manage IDA.245 Food sources such as spinach, broccoli, peas etc, which are accommodated in their diet plan and rich in iron, can be consumed.246

Patients should be advised to:
- Take oral iron supplements
- Consume non-haem foods that are rich in iron, such as legumes, peas, nuts, etc (see Figure 12)
- Consume biofortified foods
5 IDA prevention

IDA prevention requires a holistic, multi-faceted approach encompassing community consciousness, early detection of high-risk individuals, increasing iron intakes, monitoring and evaluation and proactive engagement of healthcare professionals. Public health initiatives and nutritional education are essential to reduce the prevalence of IDA in communities. This section aims to provide pharmacists with the necessary knowledge and tools to support their roles in preventing IDA in communities.

5.1 Increasing awareness and public education

The initial step in preventing IDA involves enhancing awareness about the condition and its origins. This can be achieved through public health campaigns, educational programmes, and community outreach initiatives.

Public health campaigns can inform people about the importance of iron for health, the signs and symptoms of IDA, and the ways to prevent and treat it. Pharmacists are instrumental in these initiatives, providing accurate information about IDA, its symptoms, causes and prevention strategies. However, it is important to consider the skills and knowledge required for pharmacists to contribute to these measures effectively. Pharmacists need a comprehensive understanding of IDA, including its causes, symptoms, and prevention strategies (see Section 3.1: Identification and investigation of IDA). They should be capable of identifying high-risk individuals (see Section 4: IDA management in special populations) and have knowledge about the various forms of iron supplements available (see Section 3.2.1: Iron repletion therapy).

Effective communication skills are also crucial for pharmacists to educate the community about IDA. They should be adept at explaining complex medical information in a manner that is easily understandable to the public. This includes information on dietary habits that can prevent IDA, such as iron-rich foods (see Section 3.3.1.1: Iron-rich foods).

The WHO published a comprehensive framework for action to accelerate anaemia reduction in May 2023. This framework is based on the core principles of primary health care: meeting people’s health needs through comprehensive promotive, protective, curative and rehabilitative care along the life course, systematically addressing the broader determinants of health, and empowering individuals, families and communities to optimise their health. Pharmacists can contribute to the comprehensive approach needed to address anaemia effectively and improve the overall health of individuals and communities.

5.2 Identification and screening of high-risk individuals in the population

Certain groups are more likely to develop IDA due to increased iron needs or losses, and screening can identify iron deficiency at an early stage and improve outcomes. Some examples of high-risk individuals are:

- Infants and toddlers under two years of age, due to the high iron requirements needed for their rapid growth and development.
- Children under five years of age.
- Adolescents and women of reproductive age (non-pregnant and pregnant).
- Elderly people.
- People with low dietary iron intake and micronutrient deficiencies, such as in vegetarians and vegans.
- Endurance athletes due to chronic inflammation and increased iron losses through urine and sweat.
- Individuals with chronic diseases or infections, such as malaria and worm infestation (as these infections can lead to chronic blood loss and impaired iron absorption).
- HIV (as patients may have compromised iron status due to various factors, including infection-related inflammation) and inherited disorders.
Iron deficiency anaemia: Managing symptoms and supporting self-care

- Individuals with chronic blood loss, such as heavy menstrual bleeding, chronic gastrointestinal diseases, and regular blood donation and those with gastrointestinal conditions, e.g., peptic ulcer disease. 67
- Individuals who have undergone major surgery or physical trauma.

Pharmacists can contribute to the prevention, early detection and management of IDA through the identification of signs and symptoms, point-of-care testing and referrals. They can identify these high-risk individuals by asking about their medical history, dietary habits, menstrual cycle and other risk factors (see Figure in Section 3.1: Identification and investigation of IDA.

It is reasonable to perform annual screening with complete blood count and iron studies in high-risk populations, e.g., women with heavy menstrual bleeding or a history of iron deficiency. Women in the reproductive age group can be screened every five years for haemoglobin or haematocrit. It may be reasonable to screen men and postmenopausal women once or more frequently if any risk factors are present. 21

5.3 Increasing iron intakes

A range of interventions are available for correcting IDA at the population level. These interventions, which focus on improving iron intake and bioavailability, can be implemented alone or in combination. They primarily revolve around iron supplements, nutrition education coupled with dietary modification or diversification, as well as iron fortification of foods and biofortification. 14 These strategies aim to correct iron deficiency anaemia by increasing iron intake and diversifying nutrient sources, thereby empowering individuals with informed choices for improved well-being.

5.3.1 Iron supplements

Preventive iron supplements are particularly important for paediatric populations, non-pregnant women of reproductive age, pregnant women and breastfeeding mothers. Pharmacists can advise on the appropriate type and dosage of supplements.

Generally, 1–2 mg/kg/day is the preventive dose for iron deficiency. 193 As a preventive measure against IDA, the WHO suggests daily doses of elemental iron for three consecutive months each year. 251

- For infants and young children aged six to 23 months — 10–12.5 mg of elemental iron (equivalent to 50–62.5 mg of ferrous sulfate heptahydrate, 30–37.5 mg of ferrous fumarate or 83.3–104.2 mg of ferrous gluconate) in the forms of drops, syrups or drinkable vials.
- For preschool-aged children aged 24 to 59 months — 30 mg of elemental iron (equivalent to 150 mg of ferrous sulfate heptahydrate, 90 mg of ferrous fumarate or 250 mg of ferrous gluconate) in the forms of drops, syrups, tablets or drinkable vials.
- For school-aged children aged 60 months and older — 30–60 mg (equivalent to 150–300 mg of ferrous sulfate heptahydrate, 90–180 mg of ferrous fumarate or 250–500 mg of ferrous gluconate) in the forms of tablets, capsules, syrups or drinkable vials.

For infants and toddlers, measures to prevent iron deficiency include completely avoiding cow milk and starting iron supplementation at four to six months of age in breastfed infants (this is because breast milk contains highly bioavailable iron but in amounts that are not sufficient to meet the needs of infants older than four to six months), and using iron-fortified formula when not breastfeeding. When infants are 12 months old, they should be screened for IDA.

The WHO suggests daily doses of elemental iron for non-pregnant women of reproductive age according to the prevalence as a preventive measure against IDA. 251 In areas where the prevalence of anaemia is 40% or higher, the WHO suggests non-pregnant women and adolescents of reproductive age take daily tablets of 30–60 mg elemental iron (equivalent to 150–300 mg of ferrous sulfate heptahydrate, 90 180 mg of ferrous fumarate, or 250–500 mg of ferrous gluconate) for three consecutive months each year. 7 In areas where the prevalence of anaemia is 20–40%, the WHO recommends an intermittent regimen. This involves taking one supplement weekly, containing 60 mg of elemental iron and 2,800 microgram (2.8 mg) folic acid, for three consecutive months, followed by three months without supplementation, and then resuming another three months of supplementation.163
Similarly, the WHO suggests daily doses of elemental iron for pregnant women and breastfeeding mothers. In populations where the prevalence of anaemia in pregnant women is 40% or higher, along with blood haemoglobin concentration below 11 g/dl, it is recommended to take a daily supplement containing 60 mg of elemental iron and 400 microgram (0.4 mg) folic acid throughout pregnancy. The supplementation with iron and folic acid should begin as early as possible. In populations with a 20–40% prevalence of anaemia, intermittent oral iron can be provided once a week for pregnant women. The regimen includes 120 mg of elemental iron (equivalent to 360 mg of ferrous fumarate, 600 mg of ferrous sulfate heptahydrate, or 1,000 mg of ferrous gluconate) and 2,800 microgram (2.8 mg) of folic acid throughout pregnancy. This dosing regimen is recommended as an alternative in settings where non-compliance is observed or there are concerns with women who have adequate iron intake. This dosing regimen for pregnant women aims to improve maternal and neonatal outcomes if daily iron intake is not tolerable due to side effects. The amount of elemental iron varies with different types of oral iron salts, and this is important in the choice of the preparation to dispense to a patient.

### 5.3.2 Dietary modification

Strategies aimed at dietary improvement have been directly applied to vulnerable groups, such as infants, children and pregnant women. Recognising and acting upon the critical role of correcting anaemia is essential to achieving the overarching global nutrition targets identified by the WHO, namely, stunting, low birth weight, childhood overweight, exclusive breastfeeding and wasting.

Dietary diversity refers to consuming various foods or food groups within a specific timeframe and is viewed as the most long-lasting and desirable intervention. Increasing dietary diversity implies increasing the amount of food consumed and expanding the variety of micronutrient-rich foods incorporated into the diet. Diet quality is characterised by having an adequate intake of essential macro- and micronutrients and incorporating a diverse selection of foods at the household or individual level.

Pharmacists play a crucial role in promoting these dietary changes. They can educate individuals about the importance of a balanced diet for maintaining healthy iron levels. They can advise which foods are high in iron and how to incorporate them into daily meals. They can also inform individuals about the benefits of combining iron-rich foods with foods high in vitamin C (see Section 3.3.1.1: Iron-rich foods).

### 5.3.3 Iron fortification

The WHO has recommended four types of food fortification: universal or mass fortification, open market (commercial) fortification, targeted (high-risk groups) fortification, and household and community fortification methods. Mass fortification involves adding nutrients, such as iron, folic acid, vitamin B12 or vitamin A, to commonly consumed foods, reaching a wide population. Targeted fortification focuses on specific groups with higher nutritional needs, like infants and pregnant women. Market-driven fortification refers to manufacturers adding micronutrients to processed foods to improve public health. Household and community fortification combines supplementation and fortification, particularly in enhancing foods for young children. Food fortification with suitable iron compounds is considered the best long-term method to prevent iron deficiency. Fortification with micronutrients, such as iron, aims to improve the nutritional status of populations vulnerable to micronutrient deficiencies.

Iron fortification, in contrast to supplementation, allows the delivery of lower micronutrient doses in a food vehicle, providing the option of multiple servings throughout the day. Although it takes a longer time to increase body iron levels compared with iron supplementation or iron therapy, iron fortification proves to be practical, more sustainable, and cost-effective and may be the safer intervention over the extended period for addressing iron deficiency at the national level.

### 5.3.4 Biofortification

Biofortification refers to a range of methods to counter micronutrient deficiencies by enriching the nutritional value of crops using plant breeding techniques, genetic modifications or agronomic practices. It combines conventional crop varieties with modern techniques, merging the favourable characteristics of high-iron and high-yield crop varieties, for instance, rice and legumes with higher iron content, carrots and sweet potatoes rich in beta-carotene varieties, and maize with lower phytate content (which enhances iron absorption and zinc absorption).
Biofortification aims to augment the nutritional value of staple foods, including cereals, legumes and tubers, by increasing their nutrient content, such as iron, zinc, provitamin A, amino acids and protein, during the cultivation of these plants. It plays a crucial role in supporting the health of vulnerable populations who lack access to commercially fortified foods.\textsuperscript{164, 254} Additionally, if biofortified crops possess favourable agronomic characteristics, it could result in an autonomous approach to public health, as farmers would be inclined to choose these crops.\textsuperscript{172}

Several research findings suggest that consuming iron-biofortified staple crops, e.g., biofortified millet, can effectively manage iron deficiency.\textsuperscript{259, 260} A randomised trial was carried out among adolescent boys and girls in India to investigate the effects of supplementation of iron-biofortified pearl-millet-based flatbread on iron status. The supplementation was conducted twice daily for four months. The findings suggested that supplementation of biofortified pearl millet led to a 64% reduction in the prevalence of anaemia among these schoolchildren.\textsuperscript{259}

### 5.4 Monitoring and evaluation

Pharmacists play a crucial role in preventing IDA by monitoring iron stores and ensuring adherence to iron supplementation.

- **Monitoring iron stores** — Pharmacists can monitor patients’ iron stores through point-of-care testing for haemoglobin and other relevant tests. Regular monitoring allows for early detection of iron deficiency, enabling timely intervention and preventing the development of IDA.

- **Ensuring medication adherence** — Pharmacists can ensure patients take their iron supplements as directed. This involves educating patients about the importance of regular supplementation, potential side effects, and strategies to manage them. Pharmacists can also provide reminders for refill prescriptions to ensure uninterrupted supplementation.
6 Summary and conclusions

IDA is a significant global public health concern with far-reaching implications for maternal, infant and child well-being. International targets and sustainable development goals reinforce efforts to combat this condition. Health literacy is fundamental in managing IDA, ensuring patients can make informed decisions and engage in meaningful dialogues with healthcare providers. Pharmacological treatment options, including oral iron supplements and intravenous therapy, are commonly used, along with non-pharmacological approaches that involve dietary diversification. Early identification and accurate diagnosis are pivotal in managing IDA effectively.

Despite ongoing efforts and the accessibility of treatment options, IDA affects many individuals, including special populations. The approach to effective management of IDA requires early identification, accurate diagnoses, individual-based tailored interventions and patient education. Additionally, the prevention of IDA calls for a holistic, multi-faceted approach. This encompasses enhancing community consciousness, early detection of high-risk individuals, proactive engagement of healthcare professionals and dietary enhancements.

Pharmacists play a pivotal role in raising awareness about IDA by offering accurate information regarding its symptoms, causes and preventive strategies. In a community setting, pharmacists can provide health services and information on preventing and managing iron deficiency anaemia. In a hospital setting, pharmacists can optimise patient outcomes by monitoring and adjusting treatment plans. They also actively develop evidence-based practice guidelines in collaboration with fellow healthcare professionals. Their active engagement in providing health advice has yielded significant therapeutic impact and garnered approval from fellow healthcare professionals.

To effectively contribute to these efforts, pharmacists must comprehensively understand IDA, encompassing its symptoms and preventive measures. Furthermore, they should be adept at identifying high-risk individuals and be well-versed in the various forms of iron supplements available. Collaborating with other healthcare professionals, including doctors, nurses and dietitians, is integral to providing comprehensive care for anaemic patients. This involves sharing relevant patient information and actively participating in developing and assessing patient care plans. This handbook is expected to serve as an invaluable resource, providing pharmacists, specifically in patient-facing roles, with the essential knowledge needed to address the identified gaps above in their understanding of IDA.

Further support for research and innovation in anaemia management, including diagnostic tools and treatment modalities, is necessary. Promoting continuous education through workshops, webinars and certification programmes is vital to ensure that pharmacists remain updated with the latest advancements in anaemia care. Organising workshops and group discussions based on handbook guidelines can empower pharmacists, enhancing their understanding and practical application of knowledge in the context of IDA and supporting their roles in promoting self-care to patients and communities.
7 References


Iron deficiency anaemia: Managing symptoms and supporting self-care


78.


86. BCGuidelines.ca. Iron Deficiency – Diagnosis and Management: 2019. updated [accessed: 1 September]. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/iron-deficiency.


Iron deficiency anaemia: Managing symptoms and supporting self-care


Iron deficiency anaemia: Managing symptoms and supporting self-care


Cercamondi CI, Egli IM, Mitchike E et al. Total iron absorption by young women from iron-biofortified pearl millet composite meals is double that from regular millet meals but less than that from post-harvest iron-fortified millet meals. J Nutr. 2013;143(9):1376-82. [Cited: Available at: https://www.ncbi.nlm.nih.gov/pubmed/23884388.